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A Summary 
Cytotoxic T lymphocytes (CTL) directed against the HI-viral proteins Gag and Pol have been 
shown to control HIV replication efficiently. Thus, a vaccine eliciting CTL responses against 
conserved regions of Gag might induce protection. 
Recently, in a clinical phase-I trial the immunogenicity of the vaccine candidate NYVAC-C was 
analyzed. NYVAC-C, consisting of the poxviral NYVAC vector coding for an artificial polyprotein 
Gag/Pol/Nef (GPN) as well as the envelope protein gp120 derived from the HIV-1 isolate 97CN54, 
was shown to induce only modest Gag- and Pol-specific CTL responses in few participants. The 
weak immunogenicity of NYVAC-C is believed to be evoked mainly by its low antigen expression 
rate. Thus, a new generation of immunogens based on GPN has been developed. By deletion of 
gp120, potential Env-induced suppression of Gag responses was avoided. To increase the 
steady-state levels of Gag, the natural ribosomal frameshift was reconstituted, resulting in 
expression of both, GPN and Gag. Additionally, size-reduced immunogen variants not containing 
Pol/Nef were designed. To further increase immunogenicity, antigen variants that allow formation 
of virus-like particles (VLPs) were developed. Again, due to its immunogenicity and excellent 
safety profile, NYVAC was chosen as antigen delivery system.  
Since CTL activation requires efficient peptide presentation on antigen presenting cells (APC), in 
this work, the new generation vaccines were analyzed concerning their capacity to induce peptide 
presentation on APC in an ex vivo assay. Peptide presentation on APC can be elicited by either 
intracellular (direct presentation) or extracellular immunogens (cross presentation). As a model 
system, monocyte-derived dendritic cells (mdDC) were used as APCs. Antigen presentation was 
detected by restimulation of an HIV-1 Gag-specific CTL-clone that specifically recognizes the Gag 
derived peptide GL9. 
First, to analyze the direct presentation capacity, mdDCs were infected with the vaccine 
candidates panel. As determined by restimulation of the GL9-specific CTL, immunogen-derived 
peptides were efficiently presented on mdDC despite incomplete mdDC maturation. Surprisingly, 
the weakly expressed antigen GPN induced most extensive direct presentation, whereas high 
expression of the new generation immunogens did not boost direct presentation. 
Second, for observation of cross presentation, vaccine candidate infected HeLa cells were 
analyzed to induce GL9 presentation on mdDC. Although poorly expressed in HeLa cells, GPN 
and GPN in combination with gp120 induced the most extensive CTL restimulation by GL9-cross 
presentation on mdDC. Cross presentation of the new generation immunogens was induced only 
remotely and demanded high NYVAC multiplicities. It was shown that cross presentation was 
mainly driven by vaccine infected HeLa cells whereas Gag-derived VLPs did not induce GL9 
presentation on mdDC. By using plasmid vectors as an alternative delivery system it was 
demonstrated that the unexpected low antigen presentation of the new generation antigens was 
not induced by the NYVAC vector itself. 
For further analysis of peptide presentation, restimulation of Gag-p17-specific CTL was observed. 
Presentation of the SP9 peptide was not detectable indicating that not every single peptide 
encoded in an immunogen can be presented on an APC. 
Thus, for induction of Gag specific CTL responses, the artificial polyprotein GPN appears to be 
appropriate. For better induction of CTLs in humans, more effective expression without affecting 
the immunogenic properties of GPN is required. 
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A.1 Zusammenfassung 
HIV-1 Gag und Pol spezifische zytotoxische T Lymphozyten (cytotoxic T lymphocytes, CTLs) 
können die HIV-Replikation effizient unterdrücken. Eine wirksame Impfung erfordert die Induktion 
von CTLs, die gegen konservierte Regionen im Gag-Protein gerichtet sind. 
In einer klinischen Phase-I Studie wurde die Immunogenität des Impfstoffes NYVAC-C, der für das 
künstliche Polyprotein Gag / Pol / Nef (GPN, Isolat 97CN54) sowie das Hüllprotein gp120 kodiert, 
untersucht. Der Impfstoff induzierte nur geringe Gag- und Pol-spezifische T-Zell Antworten in 
Studienteilnehmern. Es wird angenommen, dass die schwache Immunogenität der Antigene 
hauptsächlich durch deren geringe Expression verursacht wurde. Aus diesem Grund wurde eine 
neue Generation von Immunogenen basierend auf GPN entwickelt. Um die Gag-Expression zu 
erhöhen, wurde die ursprüngliche ribosomale Leserasterverschiebung wiederhergestellt, die zur 
Expression von Gag sowie GPN führt. Zusätzlich wurden verkürzte Immunogenvarianten ohne 
Pol/Nef entwickelt. Um die Immunogenität weiter zu verstärken, wurden Immunogene entwickelt, 
die die Fähigkeit besitzen, Virus-artige Partikel (virus-like particles, VLPs) zu bilden. Unter der 
Annahme, dass die Expression von Env zur Verringerung der Gag-spezifischen Immunantworten 
beiträgt, wurde gp120 in den neu-entwickelten Immunogenen nicht berücksichtigt. Zur 
Verabreichung der Immunogene wurde das gut verträgliche NYVAC-Vektorsystem verwendet. 
Die Aktivierung von CTLs erfordert effiziente Peptidpräsentation durch Antigen-präsentierende 
Zellen (antigen presenting cells, APCs). In der vorliegenden Arbeit wurden die neu-entwickelten 
Impfstoffkandidaten auf ihre Fähigkeit zur Induktion der Peptidpräsentation durch APCs in einem 
ex vivo System analysiert. Die für die Aktivierung von CTL benötigte Peptidpräsentation kann 
entweder durch intrazelluläre (direct presentation) oder extrazelluläre Proteine (cross presentation) 
hervorgerufen werden. Als Modellsystem wurden aus Monozyten generierte dendritische Zellen 
(monocyte-derived dendritic cells, mdDC) verwendet. Vakzin-induzierte Antigenpräsentation wurde 
durch die Restimulierung von Gag-spezifischen CTL-Klonen bestimmt. 
Um das Potential der Vakzinekandidaten zu untersuchen, direct presentation zu induzieren, wurden 
mdDC mit den verschiedenen Varianten infiziert. Trotz unvollständiger APC-Maturation wurde eine 
umfangreiche Präsentation des Gag-p24 spezifischen GL9-Peptides durch CTL-Restimulation 
festgestellt. Überraschenderweise induzierte das schwach exprimierte Ausgangsantigen GPN 
umfangreichere Peptidpräsentation als die stark exprimierten Immunogene der neuen Generation.  
Des Weiteren wurden die Vakzinekandidaten hinsichtlich ihrer Fähigkeit analysiert, GL9 cross 
presentation auf mdDC auszulösen. Trotz geringer Expression in HeLa-Zellen induzierte GPN bzw. 
GPN in Kombination mit gp120 die umfangreichste CTL-Restimulation durch cross presentation. 
Die Immunogene der neuen Generation induzierten cross presentation in geringerem Umfang und 
nur unter Einsatz hoher Viruskonzentrationen. Cross presentation wurde hauptsächlich durch 
infizierte Zellen ausgelöst, VLPs induzierten keine Peptidpräsentation auf mdDC. Durch die 
Verwendung von Plasmidvektoren konnte gezeigt werden, dass die unerwartet niedrige 
Antigenpräsentation nicht durch den NYVAC-Vektor selbst hervorgerufen wurde. 
Zur weiteren Untersuchung der Peptidpräsentation wurde die Restimulation eines Gag-p17 spe-
zifischen CTL-Klons untersucht. Da dieses Peptid nicht auf mdDC präsentiert wird, konnte gezeigt 
werden, dass nicht jedes im Immunogen enthaltene Peptid effizient auf APCs präsentiert wird.  
Obwohl das künstliche Polyprotein GPN die stärkste Antigenpräsentation auf APC hervorruft, 
erfordet eine effektive GPN-Vewendung in Impfstoffen eine Verstärkung der Expression, allerdings 
ohne die Immunogenität des Proteins zu verringern. 
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B Introduction 
B.1 The Human Immunodeficieny Virus (HIV) 
B.1.1 History and epidemiology 
Since its discovery in the year 1983 1, HIV distributed globally and became one of the major 
health challenges in poorly developed countries 2. UNAIDS assumes that 33.3 million people were 
HIV infected by the end of the year 2009. It is estimated that in the last ten years an average of 
2.5 million people became newly infected with HIV while 2 million AIDS related deaths occurred 
per year.  
If left untreated, an HIV infection will lead to rapid depletion of CD4+ T helper cells, thus promoting 
opportunistic infections and the development of tumors. The application of a highly active 
antiretroviral therapy (HAART) can diminish viral replication and extend the expectancy of life 3. 
However, for global control of the viral spread, HAART is unsuitable because it (i) is poorly 
distributed in developing countries, (ii) leads to adverse side effects and (iii) cannot cure 
infection4. To decelerate or suppress virus spread, the combination of risk-reduction counseling, 
distribution of condoms in poorly developed countries and the development of an efficient vaccine 
appear to be best long-term perspectives 5.   
 
B.1.2 Virus composition 
HIV, a member of the retrovirus family, is a membrane surrounded lentivirus with a single 
stranded RNA genome. The characteristics of an HIV infection are a chronical course of disease 
and a long incubation period 6,7. Since HIV is a highly diverse and variable virus, differences in the 
virus composition exist. Based on variations of the envelope protein (Env) the three major groups 
M (main), O (outlier), N (non-main or non-outlier) and P (pending the identification of further 
human cases)8 could be identified. Group M is most widespread and subdivided into the nine 
clades A, B, C, D, F, G, H, J and K. Clade B viruses have the highest prevalence in Northern 
America and Europe, while viruses of Clade C which, at the moment, elicit the highest rate of new 
infections, are mainly found in Africa and Asia 9,10. 
Virus particle composition and HIV replication have been reviewed extensively. For detailed 
description see the reference books 11,12, as well as review papers 13,14. In summary the HIV-1 
particle is 100 – 140 nm in diameter and round or icosahedral (see Fig. B1). Since the viral 
membrane has emerged from the host cell, it carries numerous cellular components such as 
surface and transmembrane proteins, as well as the viral envelope proteins gp41 and gp120. 
Each particle incorporates seven to 15 gp120 trimers on its surface, which cluster at a distinct 
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region 15. gp120 is attached to the membrane by non-covalent binding to the transmembrane 
protein gp41. The particle shape is determined by a lattice composed of matrix molecules (MA, 
p17). The p17 matrix contains a cone-shaped capsid comprising 1200 – 2000 capsid proteins 
(CA, p24), which is anchored on the matrix by p6. The capsid harbours two copies of the single 
stranded RNA genome as well as the viral proteins reverse transcriptase (RT, p66 / p51), 
nucleocapsid (NC, p7), integrase (IN, p32), protease (PR, p11), the viral regulatory protein 
negative regulatory factor (Nef) as well as the accessory proteins viral protein R (Vpr) and virion 
infectivity factor (Vif).  
 
A 
 
B 
 
 
 
 
Fig. B.1 HIV-1 structure and genome organization 16 
A, Two copies of the ssRNA bound to p6 and p7 Gag as well as viral enzymes required for viral replication 
are surrounded by a conical capsid composed of p24 Gag. A matrix consisting of p17 Gag builds a lattice 
that forms the virus particle’s shape. The host cell derived membrane harbours HIV envelope trimers and 
host cell proteins. B, Common to many retroviruses the HIV-1 genome’s structural composition is 
5’ LTR-gag-pol-env-LTR 3’. Next to the major genes coding for structural proteins the genome contains 
several non-structural accessory and regulatory genes that are unique for HIV-1  (vif, vpu, vpr, tat, rev and 
nef) 
 
Virus attachment to the cell is mediated by interactions of gp120 with the cellular CD4 surface 
receptor. CD4 is mainly expressed on cells belonging to the immune system such as 
T lymphocytes, macrophages, dendritic cells (Langerhans cells) and monocytes. The adhesion to 
CD4 leads to a conformational change of gp120 which in turn allows binding to either the 
coreceptor CCR5 or CXCR4. Rearrangements of gp41 result in a fusion of viral and host cell 
membrane. Towards uptake, the capsid is released to the cytoplasm in an uncoating process. 
Components embedded in the capsid are discharged into the cytoplasm of the host cell. 
Combined with MA, PR, NC, IN, and Vpr, the error prone RT forms a reverse transcription 
complex (RTC) which is responsible for the transcription of the RNA into dsDNA. Synthesis of the 
viral DNA genome as well as the CA dissociation induces the formation of the pre-integration 
complex (PIC) which guides the viral components to the cell nucleus. Due to signal sequences, 
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the PIC can enter the nucleus of non-dividing cells despite its size of 50 nm. The viral integrase 
inserts the HIV genome into transcriptionally active sections of the host cell’s genome. Proviral 
genes are transcribed by the cellular RNA-polymerase-II enzyme complex. Early in infection, 
mRNA coding for the proteins transcriptional transactivator (Tat) as well as the regulator of virion 
(Rev) is synthesized, initiated at promoter regions in the 5’ LTR. Tat enhances transcription rates 
by increasing RNA-Polmerase II activity. The interaction of Rev with the rev responsive element 
(RRE) located in the ORF coding for Env prevents the viral mRNA of being spliced completely 
and mediates the export of incompletely and unspliced mRNAs into the cytoplasm. Incompletely 
and unspliced mRNAs, coding for p55 Gag, GagPol, gp120 and gp41 as well as the precursor 
protein gp160, are translated at the rough ER. After trimerization, gp160 is transported to the 
Golgi complex and processed into gp41 and gp120 which are subsequently modified by 
glycosylation. In the cytoplasm the Gag precursor protein Pr55 that incorporates MA, CA, NC, p6, 
p2 and p1 as well as the GagPol protein precursor that comprises MA, CA, NC, p2, PR, RT and 
IN are synthesized. The GagPol coding mRNA is a template for the generation of both polyprotein 
precursors. A region located in the p1 and p6 ORF contains two conserved RNA elements, (i) a 
slippery site consisting of a UUUUUUA nucleotide sequence which leads to a reading frame 
switch and (ii) a stem loop region that causes a delay in the ribosomal motion. Together, both 
elements cause a -1 reading frame switch in approximately 5 % of the translation events which 
leads to the synthesis of the polyprotein precursors Gag and GagPol in a ratio of 20 : 1 17,18. To 
allow membrane anchoring, the different Gag and GagPol precursor molecules are 
post-translationally modified by myristoylation. Myristic acid, a saturated fatty acid named after the 
nutmeg Myristica fragrans, is transferred to the N-terminal Glycine residue by the enzyme 
N-myristoyltransferase 19,20. 
For efficient particle formation the transport to the plasma membrane is mediated by interaction of 
p6 with the cellular ESCRT complexes, regularly located at endosomes. Together with Env, the 
myristoylated precursor proteins Gag and GagPol are anchored into lipid raft regions in the 
plasma membrane together with the immune regulatory protein Nef which promotes virus particle 
assembly 21,22. For the formation of infective particles, two copies of the viral RNA genome are 
recruited by the interaction between a stem-loop-structure in the 5’ UTR (Ψ-site) and NC. If the 
viral genome is not synthesized in adequate amounts or packaging is defective, non infectious 
virus like particles (VLP) lacking the viral genome will be formed 23. For the generation of VLP, the 
Gag precursor protein is sufficient. 
The final budding process proceeds simultaneously to the maturation process of the viral proteins. 
Excrescence of the plasma membrane is induced by formation of a p17 lattice structure. 
Activation of the immature viral protease (PR) is induced by dimerization of GagPol. PR 
transformes the GagPol precursor protein into its maturated functional subunits. 
Introduction  6
B.1.3 Vaccination 
Underestimating the high variability of the virus, the US Secretary of Health Margaret Heckler 
stated in 1985, that a vaccine directed against HIV would be available within two years 24. By now, 
more than 35 candidate vaccines were tested in about 150 clinical phase I/II studies without 
achieving satisfactory immune protection against an HIV infection25. In the phase III clinical trial 
RV 144 (“Thai trial”) modest protection against infection was observed. Vaccination resulted in a 
31 % reduced infection rate compared to placebo receiving persons. It was the first trial which 
showed effectiveness in preventing HIV infection 26,27.  
The main obstacles in developing an effective HIV vaccine are (i) the lack of knowledge of 
immune correlates and protection, (ii) the difficulty in inducing broadly neutralizing antibodies due 
to virus variability and (iii) the absence of an animal model displaying similar disease and infection 
patterns.  
When progressing, an HIV infection leads to the formation of quasi species 28 induced by selective 
pressure driven by components of the immune system such as cytotoxic T lymphocytes (CTL). 
Viral escape mutations induced by selective pressure of the immune system are advantaged by 
the high virus replication capacity 29, the host RNA-polymerase II, as the well as the error-prone 
viral enzyme reverse transcriptase 30. Unlike other polymerases, a proofreading mechanism is 
missing, leading to an error rate of 10-3 to 10-4. Together, those processes lead to continuous 
variation in the viral genome that corrupts elicitation of a protective antibody response. 
 
B.1.3.1 Neutralizing antibodies directed against envelope proteins 
First approaches of generating immunity against HI viral infection were based on the induction of 
neutralizing antibodies against the envelope protein. This development was unexpectedly 
hampered by extensive modulations in the gp120 structure. Large gp120 variations between 
different clades 31 as well as genetic recombination of different subtypes in an infected patient  
demand the elicitation of cross reactive antibodies which are hardly achievable 32,33. Besides 
genetic variations, the accessibility of Env gp120 and gp41 epitopes is restricted by (i) N-
glycosylation 34, (ii) conformational changes elicited by trimerization 35 and CD4 receptor 
binding 36. Taken together, continuous evolution within one individual, as well as between different 
population groups and geographical regions represents a major challenge for the development of 
HIV vaccines based on broadly neutralizing antibodies 37,38.  
When starting the development of an HIV vaccine, different classical vaccination strategies were 
explored. The approaches of administering (i) formalin or heat inactivated HIV-1 particles or (ii) 
Env-based subunit vaccines such as recombinant, soluble gp120 or gp140 (gp120 combined with 
the ectodomain of gp41 induced modest titers of antibodies that could not induce statistically 
significant reduction of HIV infection 39.  
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Current research in gaining broadly neutralizing antibodies is focusing on conserved epitopes 
located in the CD4 binding site of gp120 and masked regions in gp41, which both become 
accessible when binding to the host cell 40,41.  
 
B.1.3.2 Generation of protective CTL responses 
One of the most frequently discussed issues in development of a preventive HIV vaccine is 
whether it should induce sterilizing immunity rather than improved virus control after infection 42. 
Due to HIV’s persistent life cycle, sterilizing immunity can only be achieved by hindering virus 
entry into target cells 43. CD8+ CTLs are capable of controlling HIV replication, a fact that was first 
shown by the correlation between the appearance of virus specific CTLs and the decline of the 
primary viremia in acute infections 44,45. CTL-deficient or anti-CD8+ antibody treated macaques 
show high viremia and cannot control virus infection 46. A stable, non-progressing HIV-1 infection 
in patients not generating efficient neutralizing antibodies, is usually induced by protective 
CTLs 47,48, directed mainly against HIV-1 Gag and Pol derived epitopes. Gambian and Kenyan 
seronegative sexworkers with high HIV-1 exposure were found to have HIV-1 specific protective 
CTLs 49.  
Nevertheless, CTL driven sterilizing immunity is only detected in rare cases 50. Cellular immune 
responses do not prevent the virus from generating a persistent infection. High plasma virus load 
can be observed despite high levels of HIV-1 specific CTL, mainly elicited by (i) escape mutations 
and (ii) ineffective T cell responses 51,52. The effectivity of CTL responses is highly influenced by 
the patient’s HLA-genotype (see B.2.2.3.2), which hampers the development of a universal 
vaccine mediating adequate protection independ of the HLA-type 53. 
Thus, induction of highly protective CTLs cannot prevent seroconversion but can help to control 
virus replication after infection has occurred. Reduced viral plasma load suppresses disease 
progression associated with diminished transmission rates 54. Despite all doubts concerning 
insufficient protection induced by T cell vaccination, the absence of a vaccine inducing broadly 
neutralizing antibodies demonstrates the necessity for the development of adequate T cell 
vaccines. 
 
B.1.3.3 Viral vectors as delivery systems 
In addition to naked DNA vaccines, the use of recombinant viral vectors displays the majority of 
recent studies to develop a CTL-stimulating HIV vaccine. The advantages in using viral vector 
systems are (i) high gene expression capacity, (ii) long lasting immunity, (iii) large transgene 
capacity, (iv) inexpensive manufacturing and (v) stimulation of the innate immunity 55. The risk of 
(i) reversions, (ii) uncontrolled replication, (iii) insufficient attenuation, (iv) cytotoxicity and (v) 
alteration of the host genome are the main challenges, that have to be circumvented 56.  
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To date, a variety of viral vaccine candidates were developed. They are mainly based on 
attenuated pox- and adenoviruses, some of which already are in advanced stages of clinical trials 
57. The first developed live recombinant vectors were attenuated adenoviruses as well as modified 
vaccinia viruses such as (i) canarypox virus vector (ALVAC), (ii) Modified Vaccinia virus Ankara 
(MVA), and (iii) New York Vaccinia Virus (NYVAC) 26,27,58,59. 
For opposed reasons, the two most prominent HIV-related studies are the phase II clinical trial 
V520 from Merck (STEP trial) as well as the phase III clinical trial RV144. While the RV144 trial 
was the first approach where modest protection against an HIV infection was detected 26, the 
V520 trial had to be stopped due to the lack of efficiency 60. 
Adeno-based live recombinant vectors were shown in multiple studies to elicit promising immunity 
against HIV-derived proteins while having an excellent safety profile 61. The V520 trial was based 
on the administration of three recombinant, nonreplicating, human adenovirus 
serotype 5-vectored vaccines (MRK-Ad5). The vectors contained either an HIV-1 Clade B derived 
Gag, Pol or Nef transgene. The dose-escalating, blind, placebo-controlled study included a three-
dose homologous prime / boost regimen with different amounts of viral particles. Even though no 
serious vaccine-related side effects were monitored, the study was discontinued due to the lack of 
efficiency 62. The MRKAd5-HIV gag/pol/nef vaccine did not lead to a decrease in viral plasma load 
in vaccinated individuals. HIV-1 infections occurred more often in vaccine than in placebo-treated 
patients with pre-existing adenovirus type 5 immunity 63. It is discussed controversially whether (i) 
the formation of Ad5 immune complexes created an improved environment for HIV replication in T 
cells 64 or if (ii) an Ad5 based expansion of memory CD4+ T cells with increased susceptibility for 
HIV infection induced enhanced infection rates in the MRK-Ad5 treated individuals 65. 
In the clinical phase III study RV144 a 31 % reduced infection rate of vaccinees compared to 
placebo receiving persons could be observed 26,27. This clinical study was based on a 
prime / boost regimen consisting of ALVAC®HIV vCP1521 (Sanofi Pasteur) and an AIDSVAX B/E 
(GSK) vaccine component 27. ALVAC®HIV vCP1521 was engineered to induce expression of 
subtype E HIV-1 gp120 (92TH023) linked to the transmembrane anchoring portion of gp41 (strain 
LAI), as well as HIV-1 Gag and protease (LAI strain) 58. The boosting agent AIDSVAX B/E was 
developed as a bivalent vaccine, consisting of a preparation of recombinant gp120 protein from 
two types of HIV (GNE8 and A244) 66. In the final analysis, 51 vaccine recipients became infected 
compared to 74 placebo recipients. The efficacy result was considered to be statistically 
significant 26. Taken together, the RV144 trial was the first study showing effectiveness in 
preventing HIV infection. Nevertheless, for an effective and extensive control of HIV infection the 
protectivity of AIDS vaccine candidates has to be substantially improved. 
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B.1.3.4 NYVAC as a viral vector system 
Subunit vaccines based on poxviral vectors have been studied extensively. Due to their excellent 
safety profile and immunogenic properties, these vectors display a promising vaccine delivery 
system. Additionally, the viral genome allows a long-term antigen delivery. 
Members of the poxvirus family have a large double stranded DNA genome (up to 220 kb) 
encoding several hundred proteins, each controlled by their own transcriptional promoter 67. After 
fusion, the viral core is released into the cytoplasm where transcription of early genes occurs 68. 
The early gene products are involved in viral DNA synthesis and expression of intermediate and 
late proteins such as structural proteins, enzymes, and transcription factors 69. The cytoplasmic 
virus replication occurs at replication centers or viral factories, enclosed by the rough ER 70. When 
incorporating viral DNA, immature viral (IV) particles accumulate. In a maturation process 
intracellular mature virions (MV) are formed. IMV represent the majority of infectious progeny and 
mostly remain within the cell until lysis. Some IMVs leave viral factories and become wrapped by 
a double layer of intracellular membrane derived from the early endosomes or trans-Golgi network 
to form intracellular enveloped virus (IEV) 71. After fusion with the host cell membrane, IEV lose 
their outer membrane but remain attached to the cell as cell-associated enveloped virions (CEV). 
When detaching, they form extracellular enveloped virions (EV) 72. 
Poxviruses were among the first viruses used as gene transfer vectors. Several different 
attenuated strains were utilized successfully as live vaccines against the smallpox-disease 73. 
Poxviral vectors provide high stability and ease of manufacturing as well as administration. Due to 
their genome size, they have a large packing capacity 74. The vectors were shown to induce both 
humoral and cellular immune responses against various transgens 75,76. Due to complication when 
using vaccinia viruses (VACV) as immunization agents 77, attenuated vectors such as Modified 
Vaccinia Ankara (MVA) and New York Vaccinia Virus (NYVAC) with enhanced safety profiles 
were developed. 
The highly attenuated NYVAC strain was derived from a plaque isolate of the Vaccinia 
Copenhagen strain (VACV-COP) by deletion of 18 ORFs (see C.1.4.1) affecting mainly host 
range, pathogenicity and virulence functions 78. The resulting vector was shown to have limited 
replication capacity in human cell culture lines leading to significantly diminished production of 
infectious particles. The reduced replication is triggered by increased phosphorylation of the 
initiation factor eIF-2α, which leads to a translational block of several late gene products and 
consequently the abrogation of MV formation. A correlation between blocked synthesis of late 
gene products and induced apoptosis in HeLa and mdDC was examined 79,80,81. 
Although highly attenuated, NYVAC provides a high degree of gene expression and strong 
induction of immune responses 82,81. Infected DCs are shown to (i) maturate incompletely and (ii) 
suppress expression of late viral genes only partially 79,83. The expression of viral immune 
regulators that mainly target cytokines, chemokines and TLR-signalling pathways 84 as well as the 
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incomplete maturation allow the virus to evade from antiviral host responses. However, NYVAC 
pulsed DC are successful in priming antigen specific CTL 85,86.  
Immunization studies show, that MVA and NYVAC recombinants are capable of inducing cellular 
immune responses directed against HIV in mice as well as non human primates 76,87. In humans, 
NYVAC-based HIV-1 vaccines were well tolerated and induced modest but multifunctional 
immune responses in most of the recipients in combination with DNA priming 85,88. To date, no 
NYVAC vector has reached clinical phase III, nevertheless poxviral vectors are promising 
candidates as delivery vehicles of foreign proteins and therefore can be used as effective clinical 
vaccines 89.  
 
B.2 T cell vaccine design 
CD4+ helper T cells as well as CD8+ CTLs provide potent defences against virus infections and 
intracellular pathogens 90. CTLs recognize infected or tumor cells by the binding of its T cell 
receptor (TCR) to pathogen or tumor derived peptides. TCRs recognize a single peptide bound to 
an MHC class-I molecules with high specificity. To enhance binding affinity of the TCR-pMHC 
complex, CD8-MHC contact as well as the interactions of co-receptors such as CTLA4 and CD28 
with CD80 and CD86 on professional antigen presenting cells (APC) are required 91,92. When 
attaching to target cells, CTLs induce programmed cell death by the release of cytotoxins such as 
perforin, granzymes and granulysin. After perforin-mediated induction of aqueous channels into 
the target cell’s membrane, granzymes can enter the target cell. These serine proteases induce 
apoptosis by activating caspase cascades 93,94. 
As described (see B1.3.2) CD8+ CTLs are capable of controlling HIV replication 44,95. CTL 
responses directed against HIV can be observed in long term non-progressors (LTNP) and elite 
controllers 47,48. LTNPs are individuals that can control an HIV infection without an antiretroviral 
therapy. Therefore, vaccination strategies inducing HIV specific CTLs could represent a potent 
agent to control virus spread despite not mediating sterilizing immunity. Nevertheless, previous 
vaccination approaches failed to induce protection against an HIV infection. For this reason, 
improvement of the Gag immunogen design is strongly demanded to circumvent escape 
mutations and ineffective T cell responses.  
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B.2.1 The role of dendritic cells in T cell activation and HIV infection 
B.2.1.1 General characteristics of dendritic cells 
Dendritic cells (DC), the most potent antigen presenting cells APC, are a heterogeneous group of 
cells located in blood, tissues and lymphoid organs 96. They are involved in the generation of both 
innate and acquired immune responses and are the only cells that are able to induce primary 
immune responses 97. Immature DCs are capable of taking up and processing foreign antigens 
and organisms. Subsequently, antigen presenting, maturated DCs are able to stimulate B and 
T lymphocytes efficiently. 
Dendritic cells are either of lymphoid or myeloid origin and can be diversified into different subsets 
by their anatomical distribution and cell surface markers 98. Plasmacytoid DC (pDC) and myeloid 
DC (mDC) are derived from CD34+ stem cells via the plasmacytoid or lymphoid pathway. In 
addition, DCs can be generated from blood monocytes (monocyte derived DCs, mdDC) or bone 
marrow precursors (see Tab. B.1) 99. Because of the low DC abundance in vivo, mdDC generated 
from CD14+ monocytes stimulated with IL-4 and GM-CSF, are often utilized as a model system 99. 
They offer features similar to mDCs but do not fully mimic the immunological functions of in vivo 
cells 100. 
For the disposition to take up antigens, DC precursors have to be transformed into an immature 
state induced by the cytokines GM-CSF, IL-3 and IL-4 101. Immature pDC and mDC are present in 
blood and represent 0.2 – 1% of all PBMC. Langerhans-type DC (LDC), a subset of mDC, are 
homing to epithelial surfaces where they rest in an immature state in a concentration of 0.5 –2% 
until encountering antigen 98.  
 
Tab. B.1 Characteristics and properties of different dendritic cells subsets 
Name Description and properties 
Myeloid dendritic cell 
(mDC) 
Morphology: similar to monocytes 
Functions: Major stimulator of T cells, some subsets are involved in 
wound healing 
Langerhans cells 
(LDC) 
Properties: subset of mDC, present in epidermis 
Functions: uptake and processing of microbial antigens that crossed the 
skin barrier  
Plasmacytoid dendritic 
cell (pDC) 
Morphology: similar to plasma cells 
Functions: activation of innate immune responses by interferon type I 
expression 
Monocyte derived 
dendritic cell (mdDC) 
Morphology and functions: similar to mDC 
Often utilized in research  
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Resident immature DCs possess a highly active endocytic system that is coordinated for efficient 
antigen processing. Several forms of antigen uptake are described for immature DC, such as i) 
macropinocytosis 102, ii) receptor-mediated endocytosis via C-type lectins 103, and iii) phagocytosis 
of necrotic or apoptotic cell fragments 104, viruses and bacteria 105. Besides elevated antigen 
capture by endocytosis and phagocytosis, characteristics of immature DCs are secretion of the 
cytokines IFN-α, TNF and IL-1.  
Stimuli such as bacterial lipopolysaccharide, tumor necrosis factor family ligands (TNF, CD40L, 
FasL), bacterial DNA or viral dsRNA as well as DNA can activate DCs 106. These stimulants 
interact with Toll like receptors (TLRs) present intracellularly or at the cell surface of APCs. TLRs 
activate a signal cascade that initiates maturation of DC. Maturated DCs express a large 
spectrum of chemokines such as MIP-1α, MIP-3α and RANTES to attract immature DC 107. The 
formation of a chemokine gradient leads to rapid DC accumulation at the sites of antigen 
presence within only one hour 108. Additionally, in maturated DCs molecules necessary for 
activation of T cells such as MHC class-I, and the co-receptors CD80, CD86 are upregulated. 
Maturation is linked to DC migration from skin to secondary lymph nodes, driven by the 
chemokine receptors CCR7 and CCR6 109 that mediate the escape from local MIP-3 gradients. 
Skin migration is facilitated by downregulation of the adhesion molecule E-cadherin 110, 
cytoskeleton remodelling and distribution of collagenase 111. 
After accessing the draining lymph node, mature DCs are driven to the paracortical area where 
they spread all over and form a pervasive network in T cell areas 112. To direct Ag-bearing DCs 
and naïve T lymphocytes into the paracortical area, resident mature DCs express cytokines such 
as MIP-1β 113. In the lymph node, Ag-bearing DCs encounter naïve CD4+ and CD8+ cells. For 
efficient CD8+ CTL stimulation, complete DC maturation is usually required. Therefore, CD4+ 
T helper cells specifically enhance DC maturation mediated by CD40 ligand 114 that allows 
productive CTL priming. 
 
B.2.1.2 Pathways of antigen processing and presentation in dendritic cells 
For the activation of specific CTLs in lymph nodes, DCs have to present peptides derived from 
various antigens. For peptide presentation, antigens present in the cytoplasm or collected from 
the extracellular space are processed by the proteasome into small peptides that are translocated 
by the transporter associated with antigen processing (TAP) complex into the endoplasmatic 
reticulum (see B.2.1.3.2). There they form complexes with MHC class-I molecules (pMHC) which 
are presented at the surface of DC.  
Proteasomeal protein processing in the cytoplasm is an essential cellular feature115. It plays a role 
in (i) degradation of misfolded, unfolded, damaged or mutated proteins 116,117, (ii) control of cell 
cycle and metabolic pathways 118, and (iii) recovery of amino acids maintained from the 
degradation of extracellular proteins. Intracellular antigens are degraded by an endogenous 
Introduction  13
proteolytic or lysosomal pathway, transported into the ER and loaded to MHC class I complexes. 
This process is called direct presentation 119,120. Direct presentation can result in efficient CTL 
stimulation (see Fig. B.2) and therefore is involved in controlling virus infections 121. 
Extracellular proteins, taken up by surface mannose receptors or C-type lectin receptors such as 
DC LAMP 122,123 are endocytosed and degraded via a lysosomal pathway by cathepsin proteases. 
Regularly, peptides derived from extracellular proteins are not targeted to MHC class-I 
compartments but are presented on MHC class-II molecules, that can activate CD4+ lymphocytes 
rather than CTL 124,125. Additionally, these peptides can be cross presented (see Fig. B.2) on 
MHC class-I molecules 126,127. These observations have lead to the conclusion that some DCs 
have an alternative pathway to present peptides derived from extracellular antigens 128,129. This 
pathway is believed to be necessary for the generation of immune responses against tumors 130 
and pathogens, which do not infect APC 131. Besides the generation of immune responses against 
exogenous antigens 122,132, cross presentation is also operative in the development of immune 
tolerance 133. 
Two possible routes are discussed for peptide generation in the cross presentation pathway. In 
the Tap-independent process the antigen is hydrolyzed in endosomes 134, in the Tap-dependent 
phagosome-to-cytosol-pathway, the antigen is processed in the cytoplasm 135.  
Cross presentation was described to be mainly driven by phagocytosis of cell bodies derived from 
apoptotic cells 136,137. mdDC loaded with apoptotic bodies of influenza infected HeLa cells or DC 
are capable of stimulating specific CTL 104,138. Nevertheless, structural mechanisms involved in 
cross priming are not examined accurately. Mainly, research focused on the impact of the antigen 
itself for cross presentation. It was shown that the structure and amino acid sequence of peptide 
precursor proteins affect cross presentation 139, at which sequence and length of the peptide 
flanking regions have the strongest influence140. Additionally, intramolecular localization of a given 
peptide in a protein determines the ability to be cross presented.  
It was reported, that cross presentation is an important mechanism to induce immunity against 
viral pathogens and tumors 141. Since direct and cross presentation cannot be separated in vivo, it 
remains unclear which process has most extensive impact on CTL priming. Although efficient CTL 
responses were described to be elicited by both direct and cross presentation alone, it is likely 
that both mechanisms interact in stimulating CD8+ T lymphocytes. Certainly, the pathogen itself 
dictates whether direct or cross presentation is demanded for CTL activation. Stimulation of T 
lymphocytes directed against poxviruses was found to require cross presentation 142. 
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Fig. B.2 Peptide presentation by MHC class-I molecules can be induced by direct presentation of 
intracellular antigens as well as cross presentation of endocytosed antigens. 
Generally, MHC class-I molecules present peptides that are derived by proteasomal digestion of cytosolic 
antigens. By the TAP complex these peptides are translocated into the ER where they are bound to MHC 
class-I molecules. After being located in the outer membrane, pMHC class-I complexes can activate CD8+ T 
cells. In contrast, endocytosed antigens are associated with MHC class-II molecules. When being presented 
on the cell surface pMHC class-II molecules can activate CD4+ T helper cells. In an alternative cross 
presentation pathway, endocytosed antigens can enter the route mainly found for cytosolic antigens. After 
proteasomal digestion and ER translocation, the peptides are loaded on MHC class-I molecules that can 
activate CD8+ T cells (adapted from Heath and Carbone, Nature Revues, 2001 141) 
 
B.2.1.3 Mechanisms of antigen processing and presentation 
B.2.1.3.1 Generation of antigen-derived peptides by proteasomeal digestion 
To be accessible for presentation, antigens have to be processed proteasomealy into peptides. 
Proteasomeal digestion of antigens is directly influenced by its (i) amino acid sequence and (ii) 
immunogenicity. Template dependent variations in ubiquitination and proteasome digestion result 
in different cleavage rates and pattern. Immunogenic antigens initiating innate immune responses 
can alter proteasome composition (“immunoproteasome”) and therefore influence digestion. 
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For the generation of peptides, proteins located in the cytoplasm are processed in a proteolytic 
pathway requiring ubiquitination 117. For ubiquitination of a protein substrate, a ubiquitin sidechain 
is conjugated to a lysine’s amino group by an ubiquitination-complex 117,143. The target protein’s 
amino acid sequence as well as the character of ubiquitination strongly influences the modification 
process. Large, bulky and charged N-terminal amino acid residues lead to more rapid degradation 
rates 144 and therefore effective MHC class-I presentation 145,146. By different compositions of 
ubiquitination-complexes, cells can selectively degrade proteins 117,147. Targeted degradation is 
considered to be necessary especially for regulatory molecules such as NFκB, that controls 
multiple immune responses, cell proliferation and apoptosis 118. 
Once being modified by ubiquitination, proteins are guided to cytosolic proteasomes for 
degradation. A number of studies indicate that the proteasome is a “multicatalytic protease” that 
exhibits different distinct protease activities that are driven by different subunits. The 20S core 
particle is able to process proteins after (i) basic, (ii) acidic, (iii) neutral, and after (iv) branched 
amino acids 148,149150. When entering the proteasome, the residues P1, P4 and P5 adjust the 
peptide in the active site of the proteasome, which influences processing 151.  
Protein proteolysis can by enhanced by (i) so called degron sequences 152 (ii) regions rich in 
prolin, glutamine, serine and threonine (PEST sequences) 153, as well as (iii) proline residues in 
peptide flanking regions 154,155. 
Furthermore, IFN-γ strongly influences the proteasome composition. Immunoproteasomes 
possess altered substrate properties as well as an enhanced cleavage rate. Thus, changed 
catalytic properties affect protein digestion strongly. The proteasome’s capacity to cleave peptides 
after hydrophobic residues is strongly increased whereas cleavage after acidic residues in 
reduced 156,157. Thus, due to varying peptide generation the presence of immunoproteasomes 
might induce in altered peptide presentation resulting in activation of alternative CTLs. 
 
B.2.1.3.2 Peptide translocation into the ER and formation of pMHC complexes 
For presentation on the cell surface, processed peptides are translocated from the cytoplasm to 
the endoplasmatic reticulum by the transporter associated with antigen processing (TAP). The 
TAP transporter mediates signal peptide independent translocation of peptides from the 
cytoplasm into the lumen of the endoplasmatic reticulum 158,159. Translocation of nonamers 
possessing hydrophobic C-termini is favoured by the TAP transporter 160. Amino acid exchanges 
at positions 2 to 7 rarely affect the efficiency of peptide transport whereas proline present at 
position 3 strongly improves TAP translocation 161.  
After the peptides have been transported into the ER, the assembly of peptide MHC complexes 
(pMHC) occurs 159. pMHC complexes are capable of presenting proteasomeal derived peptides to 
CD8+ T cells, thereby initiating CTL responses. The MHC heterodimer, composed of a membrane 
anchored-heavy α-chain, as well as the soluble β2-micrglobulin, is an unstable complex that is 
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stabilized upon binding an adequate peptide 162. The α-chain forms an interchain dimer, resulting 
in a peptide binding cleft 163. The genes encoding the human MHC class-I components, the 
human leucocytes antigens HLA-A, -B and –C, are located in one of the most polymorphic 
mammalian genetic loci 164. The allelic polymorphism strongly influences amino acids that 
determine specificity for foreign antigens 165,166. Most highly variable residues are found to point 
into the binding groove conferring unique peptide- and TCR-binding properties on each MHC 
molecule 167,168. The MHC complex binds peptides specifically, which strongly limits the number of 
possible binding peptides 169. Nevertheless, bound peptides vary in sequence and length although 
the MHC-I binding cleft is sterically blocked at both sites 170. This allows for the presentation of a 
large number of peptides in a limited number of MHC molecules. High diversity of peptide binding 
ensures resistance against a wide variety of pathogens, limiting immune evolvement and 
increasing breadth of peptide recognition 171. This flexibility is achieved by the structurally 
equivalent binding of only a small number of each peptide's residues 172,173.  
Binding motifs differ between different HLA alleles and are mostly influenced by character and 
number of contact sites 174. These sites are determined by individual pockets in the binding 
grooves of different HLA molecules, which leads to interaction with distinct amino acids present at 
defined positions of the peptide 175.  Specific anchor positions vary over HLA alleles, but P2 and 
P9  as well as the co-anchor P3 are mainly found to influence binding 176.  
Binding to the TCR stabilizes the pMHC complex by multiple contact sites. Different TCRs are 
found to contact different sites of the peptide and MHC side chains 177,178. Although large parts are 
buried in the MHC binding groove, bound peptides are exhibited into the TCR recognition 
surface 179. pMHC:TCR binding induces stimulation of a naïve CD8+ T lymphocytes or 
restimulation of activated CTL. 
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Fig. D.3 Activation and effector function of CTLs 
A, CTL activation is mediated specific recognition TCR:pMHC class-I interactions. The TCR binds to an 
adequate immunogen-derived peptide as well as the MHC complex itself. Efficient activation requires 
interactions between co-stimulatory molecules such as CD80 or CD86 with CD28. When interacting with 
CTLA-4, an inhibitory signal is transmitted that suppresses CTL activation. B, Infected cells can display 
pathogen derived peptides by pMHC complexes. When an adequate CTL encounters the infected cell, 
contact between both cells mediated by specific TCR:pMHC class-I interactions. The contact induces 
activation of CTL resulting in degranulation and release of perforin and granyzme. When inserting in the 
plasma membrane perforin forms pores that lead to non-specific cell lysis. Additionally, these pores allow 
granzymes to enter the target cells. Granzymes are serine proteases that induce apoptosis by activating 
caspases.  
 
B.2.1.4 The role of DCs in HIV infection 
By inducing adaptive immune responses through secretion of type-I IFN 180, as well as activation 
of B and T lymphocytes, DCs play a major role in the defence against viral infections. Certainly, 
the uptake of HIV leads to modulations in the immune stimulation capacity of DC. In HIV infection, 
DCs are not only found to have favourable effects on disease progression but next to the initiation 
of antiviral immune responses, DCs also are associated with disease progression 181. 
Accounting for approximately 80 % of new infections, heterosexual transmission is the main route 
of HIV-1 transfer. Because they are present at the oral and vaginal mucosa, DCs are among the 
first cells that encounter HIV 182. HIV can enter DCs by different pathways. In some DC 
populations such as mdDC, HIV is taken up by receptor-mediated endocytosis. The viral entry is 
mediated mainly by lectins such as DC-SIGN 183 and macropinocytosis. Some subsets express 
small amounts of CD4 as well as the coreceptors CXCR4 and CCR5. Therefore, DC-fractions are 
susceptible to HIV infection 184. Due to (i) low level receptor and coreceptor expression (ii) rapid 
degradation of internalized HIV, and (iii) host defence mechanisms only 1 - 3% of the total DC 
populations are infected productively 185. Despite the low numbers of infected cells and production 
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of virus low amounts 186 DC are jointly responsible for the spread of HIV 187. When interacting with 
T lymphocytes in the lymph node, a viral synapse allowing virus transfer between infected DC and 
lymphocytes is formed 188,189. Trans-infection of CD4+ cells mediated by DC-derived exosomes 
transmit HIV to T cells without de novo infection 190,191.  
Due to reduced maturation, infected DC are less efficient in stimulating T cells 192,193. Nef driven 
reduction in MHC levels as well as decreased levels of the corecepetors CD80 and CD86 impair 
but do not subvert T cell priming 194,195. Secondly, cytokine productions are altered in HIV infected 
DC, leading to less protective immune responses 196. 
It was shown that disease progression can be impaired by the patient’s HLA genotype 197. Three 
single nucleotide polymorphisms (SNP) that map close to the HLA loci are found to be associated 
with low levels of viremia during the asymptomatic phase of infection 198,199. The International 
Controllers Study analyzed the HLA type of an infected cohort 200. It was found that the HLA types 
B*57, B*27 and B*14 can be associated with protectivity against disease progression, whereas 
B*35 and C*07 are associated with a rapid progressor status 197,201. Two possible rationals for the 
protectivity of distinct HLA molecules are discussed. First, it was found that protective HLA 
molecules bind fewer peptides and delete fewer self-reactive T cells in the thymus giving 
HIV-specific CTL broader fine specificity 202. Thus, broader CTL responses reduce viral options for 
generating escape mutations 203,204. Secondly, protectivity could be mediated by binding of 
conserved regions of HIV-1 Gag 205. 
 
B.2.2 The role of CTL in HIV infection and vaccination 
B.2.2.1 The function and malfunction of CTL in HIV infection control 
CTLs are one of the key players of HIV control in early acute infection. The correlation between 
the appearance of virus specific CTL and the decline of primary viremia in acute infection 
demonstrate the influence of T lymphocytes on HIV replication 44,45. In acute HIV infection virus 
spread can be controlled by to CTL responses whereas in advanced disease stages virus 
replication can no longer be suppressed due to (i) viral escape mutations and (ii) a switch in CTL 
population composition 44,206,207. Additionally, the primary CTL response is directed against 
epitopes best accessible, which often do not mediate protection 208. 
Beside escape mutations, HIV strongly influences CTL population composition to escape immune 
pressure. Disease progression is not associated with the numerical loss of CTL whereas the 
number of CD4+ T helper cells is strongly decreased. In the early chronic phase, the amount of 
HIV specific CTLs in progressors is not diminished compared to LTNP 45. It was observed, that a 
skewing in CD8+ T cell differentiation leads to less functional CTL 209,210. Although recruited during 
early infection, high avidity HIV-1 specific CD8+ T cells subsequently get lost in the presence of 
persistent high-level viral replication due to a switch in clonotypic composition 211. The inefficiency 
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of CTL responses to HIV is enhanced by suppression of polyfunctional memory CD8+ CTL 
expressing Interleukin-2 (IL-2) and Interferon-γ (IFN-γ) 212. Monofunctional IFN-γ expressing 
effector cells have reduced efficiency to decelerate or inhibit disease progression. HAART treated 
individuals show high levels of IL-2 expressing HIV-specific memory T cells whose numbers 
decline when starting a structured treatment interruption (STI) 213. Beside the population 
composition switch upon entering chronic infection status, HIV leads to apoptosis of T 
lymphocytes in late chronic infection stages. The increased susceptibility to apoptosis of CD8+ 
cells correlates with disease progression 214.  
Even though present in all HIV infected individuals, the effectivity of CTL responses differs 
strongly. In patients with low or remote disease progression, a correlation between the HLA-
genotype and protectivity of CTL epitopes was observed. Therefore, to arrest HIV infection in 
early stages with low viral plasma loads, an effective CTL vaccine has to suppress the 
development of unprotective CTL as well as escape mutants. 
 
B.2.2.2 Composition of a potent HIV-1 antigen for CTL activation 
For the induction of protective CTL that decelerate or suppress viral infection, initial CD8+ T cell 
responses which have greatest impact on reducing viremia have to be intensified and stabilized 
(see B.2.2.1) 206. The strongest immune responses induced in early infection are directed against 
early regulatory and accessory proteins such as Tat, Vpr and Nef as well as the structural protein 
Gag 215,216,217. Due to their high mutation rates, accessory and regulatory proteins only play a 
minor role in the development of vaccines.  
For induction of multiepitopic immune responses, a combined administration of different viral 
proteins could improve a vaccine’s immunogenicity. Nevertheless, to date vaccination 
development mainly focuses on inducing Gag responses because of its variety of possible 
epitopes and conserved regions. Additionally, epitope enrichment within an antigen could improve 
its immunogenicity 218,219,220. On the one hand, epitope enrichment might circumvent the 
presentation of just a limited number of eptitopes and lead to the development of generalized 
vaccines, which could be administered HLA-type independently. On the other hand, a variety of 
factors influencing peptide processing and presentation (see B.2.1.3), as well as the high HIV-1 
sequence variability (see B.1.3) have to be considered. Secondly, most epitopes have been found 
to be clustering at distinct Gag regions which can impair coverage of all possible epitopes within 
one antigen 221. Furthermore, it was revealed that some epitopes - although accessible for 
presentation - were not presented to T lymphocytes. Presentation of subdominant epitopes that 
could confer protection is inhibited frequently by immunodominant peptides 222. In C57BL/6 mice it 
was shown, that the hierarchy of Dd CTL epitopes is clearly fixed. For the Lymphocytic 
Choriomeningitis virus (LCMV) model, only the three rarely presented epitopes GP-33, NPD-396 
and GP-276 are responsible for eliciting specific CTL responses 223. In HIV-1 infection, 
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crystallographic data suggested that only one peptide can adequately bind to HLA-B*2705, 
whereas no well-defined HLA-A*1 restricted epitopes has been described 224,225. 
Even though escape mutations complicate the development of effective immunogens, induction of 
broadly cross reactive CTLs could circumvent this obstacle 226,227. The HLA-A*2 restricted 
Gag-p17 epitope SL9 (SLYNTVATL, residues 77-85) is the best defined and examined HIV-1 
epitope 228,229. It was shown, that the immunodominant SL9 pepitde is found in approximately 70% 
of all HLA-A*2 patients in acute HIV infection whereas in chronic infection only a small part of 
patients presented this epitope indicating escape mutations 230.  
To enhance immunogenicity, antigens capable of inducing cross priming of CTL are preferably 
employed as a vaccine. Especially when using vector systems that do not directly affect 
professional APCs, such as poxviral vaccines 142,231, antigens designed for enhanced cross 
priming capacity are demanded. Besides the protein half-life and amino acid sequence (see 
B.2.1.3), the accessibility of extracellular antigen is strongly facilitating cross presentation. The 
ability of Gag to form virus like particles (VLP) leads to elevated amounts of HIV-1 proteins being 
presented extracellularly. VLPs represent a form of subunit vaccines that are able to self 
assemble into an organized particle structure 232,233. Due to the lack of regulatory proteins as well 
as genetic material, VLPs are both replication and infection incompetent. VLPs can efficiently 
induce cross presentation leading to MHC-class-I presentation of HI-viral antigens 234,235. For VLP 
uptake, various mechanisms such as phagocytosis, clathrin-mediated uptake, non-clathrin-
mediated uptake and macropinocytosis were described 236. Most VLP models have been shown to 
induce activation and maturation of DC through TLR2 and TLR4 237,238. In animal models, VLPs 
were shown to induce both mucosal and systemic immune responses 239. Especially when used in 
prime / boost regimens, VLPs induce cellular and humoral immune responses in mice 240,241. 
 
B.2.2.3 The clinical phase-I trials EuroVacc01 and EuroVacc02 
For the development of a safe and effective HIV-1 vaccine, novel polyepitopic antigens were 
engineered and analyzed by the EuroVacc foundation 85,88,242. The most promising vaccine 
candidate was designed as a bivalent vaccine consisting of both the artificial polyprotein 
Gag/Pol/Nef (GPN) and gp120 based on the C-clade 97CN54 provirus isolate collected in 
Sianking province (China) 243. For safety issues, several modifications were introduced such as (i) 
abrogation of VLP formation by interrupting the Gag myristoylation signal (G2A), (ii) inactivation of 
the protease (D577N), (iii) an exchange of C- and N-terminal regions in the nef gene sequence 
(nucleotides 8,170–8,469 linked to 3′ end of nucleotides 8,470–8,787), as well as (iv) interruption 
of the Pol ORF by inserting the scrambled nef sequence at position 2,406 – 2,527 (see C.1.3). 
Due to an excellent safety profile and immunogenic properties of the vector, the GPN and gp120 
gene sequences were inserted into TK locus of NYVAC (NYVAC-C). Transgene expression was 
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driven by a bidirectional NYVAC early / late (E/L) promoter. Thus, gene expression leads to equal 
amounts of GPN and gp120. 
In the two clinical phase-I trials EuroVacc01 and EuroVacc02 (EV01 and EV02), immunogenicity 
and safety issues of the polyepitopic C-clade antigen were evaluated 85,242. No serious adverse 
events were monitored in the placebo-controlled phase-I study EV01 242. In the EV02 study, the 
administration of NYVAC-C resulted in modest cellular immune responses in some patients 
mainly directed against HIV-1 gp120, whereas Gag, Pol and Nef specific responses were 
detected to be weak (see Fig. D.4). Since (i) protective CTL epitopes were found to be mainly 
located in Gag and Pol and (ii) Gag comprises several highly conserved regions, a vaccine that 
induces Gag-specific CTL is believed to mediate protection 215,216,217. Thus, NYVAC-C did not fulfil 
the demanded vaccine characteristics.  
Thus, for expanding breadth and depth of the Gag specific immune responses a new generation 
of immunogens was developed (see D.1). Based on the results of the EuroVacc studies it was 
estimated that gp120 negatively influences Gag-specific CTL responses. Additionally it was 
assumed, that GPN size reduces expression strongly. Thus, the new generation immunogens 
were considered to (i) be expressed more efficiently, (ii) increase cross presentation, and (iii) 
avoid replacement of Gag epitopes by immunodominant Env, Pol or Nef peptides (see D.1). 
 
                   A                        Env  
 
B              Gag / Pol / Nef 
 
Fig. D.4 HIV-specific T cell responses detected in PBMC of participants of the clinical phase-I trials 
EV02 
Human volunteers were inoculated with DNA-C (week 0 and 4) and boostered with NYVAC-C (week 20 and 
24). PBMC were isolated, restimulated and analyzed in an IFN-γ ELISPOT assay. (A) Median magnitude of 
Env-specific T cell responses at different time points across the duration of the study; (B) Median magnitude 
of Gag-, Pol-, and Nef-specific T cell responses at weeks 26 and 28. 88. 
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B.2.3 Objective of the present study 
Gag-specific cytotoxic T lymphocytes (CTL) play a major role in HIV infection control. Thus, 
vaccination requires efficient induction of Gag-specific CTL. For this purpose, the vaccine 
candidate NYVAC-C has been developed by the EuroVacc foundation. In the clinical phase-I 
study EuroVacc02 the vaccine candidate NYVAC-C failed to induce extensive T cell responses 
which was most likely provoked by modest immunogen expression. On this account, 
NYVAC-based vaccine candidates with newly designed immunogens, based on the initial GPN 
polyprotein that was applied in NYVAC-C, were developed. Since stimulation of CTL was believed 
to require efficient antigen levels, the immunogens were designed to be extensively expressed. 
To increase the steady-state levels of Gag, the natural occurring ribosomal frameshift was 
reconstituted resulting in expression of both Gag and GPN in a ratio of 95:5. Additionally, to 
reduce the immunogens’ size further, several immunogen variants not containing Pol/Nef were 
developed. Since extracellular proteins can induce cross presentation, which promotes efficient 
vaccination, budding competent immunogens were designed. Assuming that Env expression 
could reduce Gag-specific immune responses, no vaccine variants coding for gp120 were 
developed. 
The objective of this work was the detailed immunological characterization of the novel vaccine 
candidates in human ex vivo models. Initiation of cellular immune responses by direct 
presentation depends on efficient peptide presentation on antigen presenting cells (APC) which 
requires sufficient immunogen expression as well as APC maturation. Therefore, the novel 
vaccine candidates should be analyzed for induction of maturation and immunogen expression in 
monocyte derived dendritic cells (mdDC). Peptide presentation ought to be determined by 
restimulation of different HIV-Gag specific T cell clones. 
Besides direct presentation, cross presentation represents an alternative way of generating 
CTL-based immune responses. Cross presentation requires availability of immunogens 
expressed by cells other than APC. Therefore, the vaccine candidates should be analyzed for 
induction of immunogen expression in epithelial HeLa cells and their capacity to be cross 
presented on APC which was analyzed by restimulation of Gag-specific CTL clones. 
The obtained results will form the basis for further refinement of the immunogen candidates to 
yield an optimal next-generation T cell-vaccine directed against HIV-1. 
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C Material and methods 
C.1 Material 
C.1.1 Cells 
C.1.1.1 Prokaryotic cells 
The bacterial strains DH5α and DH10B were used for the amplification of plasmid DNA. 
Tab. C.1 Bacterial strains 
Strain Genotype 
DH5α F- supE44 ∆lacU169 (φ80 lacZ∆M15) hsdR1 recA1 endA1 gyrA96 thi-
1 relA1 244 
DH10B araD139 ∆(ara,leu)7649 galU galK rspL nupG (Gibco BRL)  
 
C.1.1.2 Eukaryotic cell lines 
All eukaryotic cell lines were maintained under conditions of 5% CO2 and 37°C. 
Tab. C.2 Eukaryotic cell lines 
Strain Description 
DF-1 spontaneously immortalized chicken cell line derived from 10 day old 
East Lansing Line (ELL-0) eggs, ATCC: 12203 245 
BHK-21 Hamster kidney fibroblast cell line, ATCC: CCL-10 246 
HeLa Human epithelial cell line derived from a cervix carcinoma, 
ATCC: CCL-2 247 
LCL - HLA-A*2 EBV transformed lymphoblastoid cell line derived from an HLA-A*2 
positive donor, Vaecgene Biotech GmbH 248 
LCL – HLA-B*07 EBV transformed lymphoblastoid cell line derived from an HLA-B*07 
positive donor, Vaecgene Biotech GmbH 248 
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C.1.2 Bacterial growth and cell culture media and buffers 
Tab. C.3 Bacterial growth medium and buffers 
Description Ingredients 
LB (lysogeny broth) Yeast extract 0.5 % (w/v), tryptone 1 % (w/v), 
NaCl 1 % (w/v), pH 7.4 
TB1 (Transformation buffer 1) RbCl 100 mM, MnCl2 50 mM, KAc 30 mM, 
CaCl 10 mM, glycerine 15 % 
TB2 (Transformation buffer 2) MOPS 10 mM, RbCl 10 mM, CaCl2 75 mM, 
glycerol 15 % 
RIPA buffer Tris 50 mM, NaCl 150 mM, SDS 0.1 %, Na-
desoxycholate 0.5 %, Triton X-100 1 %, pH 8,0 
Complete Mini protease inhibitor (Roche, 
1 tablet / 10 mL buffer) 
 
Tab. C.4 Cell culture media and buffers 
Description Ingredients 
DMEM Dulbecco’s modified Eagle’s medium 
DMEM-10  DMEM, FCS 10 % (Gibco), penicillin 
100 U/mL, streptomycin 0.1 mg/mL 
RPMI1640 Roswell Park Memorial Institute medium  
RPMI1640-10  RPMI1640, FCS 10 % (Lonza), penicillin 
100 U/mL, streptomycin 0.1 mg/mL 
RPMI1640-10/50  RPMI1640, FCS 10 % (Lonza), Hepes 50mM, 
IL-2 10 U/mL, PHA-L 1 µg/mL, penicillin 
100 U/mL, streptomycin 0.1 mg/mL 
mdDC-medium  RPMI1640, FCS 10 % (Lonza), Pan Vitamins 
1x, MEM 1x, L-glutamine 20 mM, pyruvate 1x, 
β-mercaptoethanol 0,05 mM, IL-4 500 U/mL, 
GM-CSF 500 U/mL, penicillin 40 U/mL, 
streptomycin 40 µg/mL 
Storage medium RPMI1640, FCS 50%, DMEM 10%, penicillin 
100 U/mL, streptomycin 0.1 mg/mL 
IMDM Iscove’s modified Dulbecco’s medium 
IMDM-8-10  IMDM, FCS 8% TCGF 10%, IL-15 10 ng/mL, 
penicillin 100 U/mL, streptomycin 0.1 mg/mL 
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Description Ingredients 
MACS buffer PBS, BSA 0.5%, EDTA 2 mM 
P2 PBS, FCS 2% 
FACS buffer PBS, FCS 1%, NaN3 1 mg/mL 
Perm / wash buffer PBS, saponine 0.5% 
Fixation buffer PBS, saponine 1%, PFA 4% 
TE buffer Tris 10 mM, EDTA 1 mM, pH 7.5 
 
 
C.1.3 HI-viral immunogens 
The HI-viral immunogenes were derived from a C-clade 97CN54 or 97CN001 provirus clone 
collected in Sianking province (China) 243. The gpn, gag and env genes were RNA and codon 
optimized by using the GeneOptimizer software package (Geneart AG, Regensburg; 249).  
 
Tab. C.5 Specificties of HIV-1 derived immunogens 
Antigen  Specificities 
gpn / gp120 
(bidirectional) 88 
isolate 
gp120 
 
gag 
pol 
 
 
 
nef 
97CN54 (Prot-) 
artificial signal peptide (MDRAKLLLLL LLLLLPQAQ), nucleotides: 
5,673–7,109; 
G2A mutation (Myr-), nucleotides: 167–1,651; 
5’ part: D577N mutation (Prot-), ∆rt nucleotides:1,444–2,406 
3’ part: RT insertion, ∆int, nucleotides: 2,527–3,591; 
inserted in rt locus, 
nucleotides 8,170–8,469 linked to 3′ end of nucleotides 8,470–
8,787 
gpn (∆FS, Myr-) isolate 
gag 
pol 
 
 
nef 
97CN001  
G2A mutation (Myr-), nucleotides: 167–1,651; 
5’ part: ∆rt nucleotides:1,444–2,406 
3’ part: RT insertion, ∆int, nucleotides: 2,527–3,591; 
inserted in rt locus, 
nucleotides 8,170–8,469 linked to 3′ end of nucleotides 8,470–
8,787 
gpn (FS, Myr-) isolate 
gag 
97CN001 
G2A mutation (Myr-), nucleotides: 167–1,651; 
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Antigen  Specificities 
FS 
pol 
 
 
nef 
inserted at positions 1293-1345 in the gpn construct 
5’ part: ∆rt nucleotides:1,444–2,406 
3’ part: RT insertion, ∆int, nucleotides: 2,527–3,591; 
inserted in rt locus, 
nucleotides 8,170–8,469 linked to 3′ end of nucleotides 8,470–
8,787 
gpn (FS, Myr+) isolate 
gag 
FS 
pol 
 
 
nef 
97CN001 
nucleotides: 167–1,651; 
inserted at positions 1,293–1,345 in the gpn construct 
5’ part: ∆rt nucleotides:1,444–2,406 
3’ part: RT insertion, ∆int, nucleotides: 2,527–3,591; 
inserted in rt locus, 
nucleotides 8,170–8,469 linked to 3′ end of nucleotides 8,470–
8,787 
Gag (Myr-) 249 isolate 
 
97CN001 
G2A mutation (Myr-), nucleotides: 167–1,651 
Gag (Myr+) 249 isolate 
 
97CN001 
nucleotides: 167–1,651 
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C.1.4 Viruses 
C.1.4.1 General 
NYVAC (New York Vaccinia virus) is a highly attenuated virus strain. It was derived from the 
Copenhagen vaccinia strain by the deletion of 18 ORF that influence virulence, host range and 
pathogenesis of the virus 78. 
 
C.1.4.2 NYVAC with HIV-1 derived transgenes 
The HIV-1 transgenes (see C.1.3) were inserted by recombination at the J2R locus under the 
control of a vaccinia early / late promoter. 
 
Tab. C.6 Properties of the NYVAC based vaccine candiates 
Description HIV 
frameshift 
Myristoylation 
site 
Transgene specifications 
NYVAC-C - - Expression of HIV-1 gp120 and 
GPN polyprotein under the control 
of a bidirectional promoter, 
no VLP budding 
NYVAC-gpn (∆FS, Myr-) - - Expression of the GPN 
polyprotein, no VLP budding 
NYVAC- gpn (FS, Myr-) + - Expression ratio of 95 % Gag and 
5% GPN (estimated) 250, 
no VLP budding 
NYVAC- gpn (FS, Myr+) + + Expression ratio of 95 % Gag and 
5% GPN (estimated) 250, 
VLP budding 
NYVAC-gag (Myr-)  - Expression of HIV-1 Gag, 
no VLP budding 
NYVAC-gag (Myr+)  + Expression of HIV-1 Gag, 
VLP budding 
NYVAC-gp120   Expression of HIV-1 gp120, 
NYVAC-wt   no transgene 
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C.1.5 DNA 
C.1.5.1 Oligonucleotides 
Tab C.7 Oligonucleotides for sequence analysis  
Description Sequence (5’→3’) Transgene 
97CN001-SynGag-SQP_402 fw CCTGCAGGGCCAGATGGTGC gpn/gag 
97CN001 580R GTCCTTCAGGATCTGCATAG gpn/gag 
Syn-GPN_681 fw GCCCAGGGGCAGCGACATCG gpn/gag 
GPN 1280F CAGATGAAGGACTGCACCGA gpn/gag 
GPN 1780F  CGTGCTGGAGGACCTGAACC gpn 
GPN 2290F GAAGAAGAGCTGACCGTGC gpn 
GPN 2790F  CCGAGTTCTACAAGGACTGC gpn 
GPN 3280F CAAGCTGAACTGGGCCAGCC gpn 
CN54 3701F AGTGGGAGTTCGTGAACACC gpn 
97CN001-SynGag-SQP_901fw CTGCGGGCCGAGCAGGCCAC gpn 
C-synenv 1208(120b) GGTGGTGGCGCCCTTCCACAC gp120 
CN54_Env_620F TGCAACACCAGCGCCATCAC gp120 
Env 320R CGCAGGGCTTCAGGCTCTGG gp120 
97CN001_290F GAGATCGACGTGCGGGACAC gp120 
CN54_Env_1120F CAGCGGCGGCGACCTGGAGG gp120 
 
C.1.5.2 Vectors 
Tab. C.8: Commercial DNA-Vectors 
Description Specification (Supplier) 
pcDNA3.1(+) Eukaryotic expression plasmid (Invitrogen, Karlsruhe) 
pcDNA3.1(-) Eukaryotic expression plasmid (Invitrogen, Karlsruhe) 
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Tab. C.9: Properties of plasmids coding for HIV-1 derived antigens 
Description HIV 
frameshift 
Myristoylation 
site 
Transgene specifications 
pcDNA-3.1(+)_gpn (∆FS, Myr-) - - Expression of the GPN 
polyprotein, no VLP budding 
pcDNA-3.1(+)_gpn (FS, Myr-) + - Expression ratio of 95 % Gag 
and 5% GPN (estimated) 250, 
no VLP budding 
pcDNA-3.1(+)_gpn (FS, Myr+) + + Expression ratio of 95 % Gag 
and 5% GPN (estimated) 250, 
VLP budding 
pcDNA-3.1(-)_gag (Myr-)  - Expression of HIV-1 Gag, 
no VLP budding 
pcDNA-3.1(-)_gag (Myr+)  + Expression of HIV-1 Gag, 
VLP budding 
pcDNA-3.1(+)_gp120   Expression of HIV-1 gp120, 
NYVAC-gfp   Expression of humanized 
green fluorescent protein 
 
C.1.6 Antibodies 
C.1.6.1 Western blot antibodies 
Tab. C.10: Primary and secondary Western blot antibodies 
Description Supplier / Company   Specifications 
CB-4/1 Charité Berlin, Prof. Dr. 
W. Höhne 
Monoclonal mouse Ab raised against HIV 
clade C capsid protein (p24)  
Dilution 1:1000 
Anti-mouse IgG 
HRP-conjugated 
Dako, Hamburg HRP conjugated goat Ab raised against 
mouse  IgG 
Dilution: 1:2000 
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C.1.6.2 FACS antibodies 
Tab. C.11: FACS antibodies for ICS and surface protein staining 
Description Supplier / Company Specifications 
KC-57 RD1 Beckman Coulter Monoclonal mouse Ab raised against HIV 
clade C capsid protein (p24)  
Volume / test: 2µl 
Anti-human CD80 
FITC-conjugated 
BD Pharmingen Monoclonal mouse Ab raised against human 
CD80 
Volume / test: 2µl 
Anti-human CD86 
V450-conjugated 
BD Pharmingen Monoclonal mouse Ab raised against human 
CD86 
Volume / test: 3µl 
Anti-human HLA-DR 
APC-conjugated 
BioLegend Monoclonal mouse Ab raised against human 
HLA-DR 
Volume / test: 4µl 
Anti-human CD8 
APC-Cy7-conjugated 
BD Pharmingen Monoclonal mouse Ab raised against human 
CD8 
Volume / test: 3µl 
Anti-human IFN-γ 
FITC-conjugated 
BD Pharmingen Monoclonal mouse Ab raised against human 
IFN-γ 
Volume / test: 2µl 
 
C.1.7 Cytokines and growth factors 
Tab. C.12: Cytokines and growth factors 
Description Supplier / Company Specifications 
Human IL-2 Miltenyi Biotec GmbH 50 U/mL 
Human IL-4 Cellgenix Technology 
Transfer Gmbh 
500 U/mL 
Human IL-15 Cellgenix Technology 
Transfer Gmbh 
10 ng/mL 
TCGF Helvetica Healthcare Final concentration:  
10% in RPMI 
GM-CSF (LeukineTM) Genzyme 500 U/mL 
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C.1.8 Cell culture agents 
Tab. C.13: Cell culture agents 
Description Supplier / Company Specifications 
PHA-L Sigma Aldrich 1 µg/mL 
BFA Biochrom AG 1 µg/mL 
LPS Sigma Aldrich 100 ng/mL 
 
C.1.9 Peptides 
Tab. C.14: Synthetic peptides for CTL stimulation 
Description Supplier / Company Specifications 
GPGHKARVL (GL9) Biosynthan GmbH Origin: HIV-1 Gag p24 
Residues: 223-231 
Restriction: HLA-B*07 
Concentration: 3 µg/mL 
SLFNTVATP (SP9) Biosynthan GmbH Origin: HIV-1 Gag p17 Residues: 77-85 
Restriction: HLA-A*2 
Concentration: 3 µg/mL 
SLYNTVATL (SL9) Biosynthan GmbH Origin: HIV-1 Gag p17 Residues: 77-85 
Restriction: HLA-A*2 
Concentration: 3 µg/mL 
 
C.1.10 Commercial kits 
Tab. C.15: Commercial kits 
Description Supplier 
Endotoxin free DNA preparation Maxi kit Qiagen Hilden 
Amobocyte Lysate QCL-1000 kit Lonza Group LTD 
 
C.1.11 Chemicals and plastics 
If not further specified, all chemicals were purchased Sigma and Merck, cell culture flasks as well 
as general plastic material from BD Falcon and cell cultural supplies by PAN Biotech, GibcoBRL 
and Lonza Group LTD. 
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C.2 Microbiological techniques 
C.2.1 Growth and selection of bacteria 
Bacterial cultivation was performed overnight in LB medium at 37°C. For the selection of 
transformed bacteria, LB medium with 100 µg/mL ampicillin was used. 
C.2.2 Generation of chemically competent bacteria 
Chemically competent bacteria were obtained by the use of the RbCl method 244. All steps were 
performed at 4°C, centrifugation steps were performed at 2000 x g for 15 min. 
50 mL of an E.coli overnight culture were inoculated in 450 mL LB medium and incubated at 
37 °C until reaching an optical density of OD600 = 0,4. After centrifugation, the bacteria were 
resuspended in 16 mL chilled TB1 and incubated on ice for 15 min. Afterwards the cells were 
centrifuged and the pellet was resuspended in a final volume of 3 mL cooled TB2, divided in 
100 µL aliquots and stored at -80°C. 
C.2.3 Transformation of chemically competent bacteria 
For the transformation 100 µL of chemically competent bacteria (C.2.2) were thawed on ice, 
mixed with 1 µg plasmid DNA and incubated on ice for 10 min. For transformation, the bacterial 
cell wall was permeabilized by heat induction at 42°C for 1 min, followed by incubation on ice for 
1 min. After addition of 500 µL LB medium, the cells were incubated at 37 °C for 1 h with shaking 
at 300 rpm and subsequently plated on LB agar selection plates containing appropriate 
antibiotics. 
 
C.3 Molecular biology techniques 
C.3.1 DNA purification 
To avoid contaminations with immune modulatory bacterial components such as LPS 
(lipopolysaccharide) in cross presentation studies, endotoxin-free plasmid DNA was generated 
using an Endotoxin-free DNA preparation Maxi kit (C.1.10). 
The eluted DNA was resuspended in TE-buffer and the concentration was measured by 
photometric analysis (Nanodrop-1000 spectrophometer, Peqlab). The LPS content was 
determined with the Amobocyte Lysate QCL-1000 kit (C.1.10).  
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C.3.2 PCR analysis 
The inserted transgenes (C.3.1) were verified by polymerase chain reaction (PCR) 251 analysis. 
The DNA was screened using adequate primer pairs (C.1.5) and the 2x PCR Master Mix 
(Promega, Madison, USA). The DNA was amplified in 25 cycles (denaturation 94 °C, 30 s; 
Annealing 58 °C, 30 s; extension 72 °C, 60 s; final elongation 72 °C, 15 min). 
To determine PCR efficiency the generated DNA fragments were analyzed for correct size by 
agarose gel-electrophoresis (1% agarose in TBE buffer; Tris 89mM, boric acid 89mM, EDTA 
2mM, ethidium bromide 0.01%). 
 
C.4 Protein biochemistry techniques 
C.4.1 Sample processing for protein immunostaining 
For protein analysis by immunostaining, secreted proteins have to be concentrated (C.4.1.1), 
intracellular proteins have to be released from the cells (C.4.1.2). All sonication steps were done 
with a Sonifier 450 (Branson) at 50 % exposure time and 80 % max. output power. The protein 
concentration was determined prior to use in immunostaining assays by spectrophotometry 
(C.4.1.3) 252. 
 
C.4.1.1 Concentration of secreted proteins 
For concentration of secreted proteins, the supernatant of infected cells was collected and Na-
desoxycholate was added to a final concentration of 0,2%. After incubation for 5 min at 4°C, the 
sample was sonicated for 1 min and mixed with TCA to a final concentration of 5,5% TCA. The 
aggregated proteins were pelleted (8.000 x g, 10 min, 4°C) and subsequently resuspended in a 
desired volume of dH2O. 
 
C.4.1.2 Cell lysis 
To analyze intracellular proteins by immunostaining, the cells were washed with PBS, harvested 
and pelleted (2.000 x g, 10 min, 4°C). The pellet was resuspended in 100 µL RIPA buffer (C.1.2), 
incubated for 1 h at 4°C and sonicated for 1 min for complete cell lysis. Subsequently, the cellular 
debris and insoluble components were pelleted by centrifugation (2.000 x g, 10 min, 4°C) and the 
protein concentration of the supernatant was determined (4.1.3). 
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C.4.1.3 Determination of protein concentrations 
The concentration of total protein amount was determined using the protein assay according to 
Bradford by measuring the 595 nm absorption of proteins bound to chromogenic substrates 252. 
The proteins were stained with the BioRad protein assay (BioRad, Munich) according to the 
manufacturer’s instructions. For protein quantification, a calibration line based on the linear 
regression model was determined with BSA solutions of distinct concentrations. 
 
C.4.2 Protein immunostaining 
C.4.2.1 SDS-PAGE and Western blot analysis 
Electrophoretic protein separation was performed as described by Laemmli 253. Protein samples of 
cell lysates (4.1.2) and supernatants (4.1.1) were mixed with 2x sample buffer (Tris/HCl 120mM 
pH 6,8, SDS 2 % (w/v), β-mercaptoethanol 10 %, EDTA 1 mM, glycerol 10 % (w/v), bromophenol 
blue 0,01 % (w/v)) and heated for 5 min at 95°C. 
The separated proteins were then transferred onto nitrocellulose membranes by Western blotting 
using a semi-dry blotting device (Serva Electrophoresis GmbH) according to manufacturer’s 
instructions. Subsequently the nitrocellulose membrane was incubated for 1 h in MTBS buffer 
(NaCl 150 mM, Tris/HCl 50 mM, skim milk powder 5 % (w/v), pH 7.4) to saturate unspecific 
antibody binding areas on the membrane. For protein immunostaining, the primary and secondary 
antibodies (C.1.5) were diluted appropriately in MTBS buffer, incubated for 1 h and subsequently 
washed three times with TTBS buffer (NaCl 150 mM, Tris/HCl 50 mM, Tween-20 0,3 %, pH 7.4). 
Protein bands were visualized by enhanced chemiluminescence using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Solutions) according to the supplier’s instructions and 
detected with a ChemiluxPro device (Intas Science Imaging Instruments GmbH, Göttingen). 
 
C.4.2.2 Flow cytometry analysis (FACS) 
The specific detection of proteins by flow cytometry was performed in 96-well U-formed reaction 
plates, centrifugation steps were done at 300 x g for 5 min at 4 °C. 1x104 cells were analyzed in a 
FACS Canto II device (BD, FACS Diva v6.0 software). 
 
C.4.2.2.1 Detection of surface proteins in FACS analysis 
For immunostaining of proteins expressed on the cell surface, cells were pelleted and washed 
twice in 200 µl chilled FACS buffer to interrupt the cell metabolism. The incubation of the specific 
antibodies (C.1.5.3) was done for 25 min at 4°C under light exclusion in 50 µL FACS buffer. After 
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staining, unbound antibodies were removed by two washing steps with 200 µl FACS buffer. For 
analysis or storage, the cells were resuspended in 100 µl chilled FACS buffer. 
 
C.4.2.2.2 Detection of intracellular proteins / Intracellular cytokine staining (ICS) 
For intracellular detection of regularly secreted proteins such as cytokines by FACS analysis, cells 
were cultivated with the intracellular transport blocking agent Brefeldin A (BFA, 0.1 µg/mL,  C.1.8). 
Cells were pelleted by centrifugation and washed twice in 200 µl chilled FACS buffer to interrupt 
the cell metabolism 254. After treatment with buffer cells were washed twice with 100 µl 
Perm / Wash buffer (C.1.2). The appropriate antibodies (C.1.5.3) were diluted in 50 µL 
Perm / Wash buffer and incubated for 25 min at 4°C under light exclusion. To remove unbound 
antibodies cells were washed four times with 200 µL Perm / Wash buffer. For analysis or storage, 
the cells were resuspended in 100 µl chilled FACS buffer. 
 
C.5 Cell culture techniques 
C.5.1 General infection procedures 
C.5.1.1 Generation and maintenance of mdDC 
Monocyte derived cells (mdDC) were generated by a modified protocol described by Thurner 255. 
For the generation of approximately 1x107 mdDC, PBMC were isolated from a 50 mL blood 
sample using Leucosep tubes (Greiner Bio-one) according to the supplier’s manual. The buffy 
coat was washed twice with P2 buffer (C.1.2), the cell count was determined in a Vi-Cell device 
(Beckman Coulter). Monocytes were isolated with CD14 microbeads in a MACS assay (Miltenyi 
Biotec GmbH) according to the manufacturer’s instructions. For cell differentiation, the obtained 
cells were counted, set to a cell density of 1x106 / mL and incubated for 5 - 6 d in mdDC medium 
(C.1.2) supplemented with IL-4 and GM-CSF (C.1.6). 
 
C.5.1.2 Proliferation assay for CTL cell clones 
Cytotoxic T lymphocytes (CTL) were proliferated with HLA matching LCL feeder cells (Vaecgene 
Biotech GmbH). After incubation with the corresponding peptide (C.1.8) for 2-3 h at 37°C in 
RPMI1640-10 medium (C.1.2; 1 mL/1x107 cells), the LCL cells were irradiated with 60 gy in a 
gamma ray device and subsequently diluted in IMDM-8-10 medium (C.1.2; 10 mL/1x107 cells) 
with IL-15 (C.1.6). The feeder cells were cocultivated with 1x106 freshly thawed CTLs. The 
solution was transferred into 96-well U-formed reaction plates (100 µL/well) and incubated at 
37 °C and 5 % CO2. Medium was refreshed in a three-day repetition by exchanging 50 µL 
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medium. After a 14-day period, the CTL were frozen using an Ice Cube 14S cell freezer device 
(SY-LAB) in storage medium (see. C.1.2). 
 
C.5.1.3 Transfection of human cell lines 
Human cell lines were transfected with Lipofectamine 2000 (Invitrogen, Life Technologies) 
according to the manufacturer’s instructions. 
 
C.5.1.4 Infection of human cell lines with NYVAC 
For the infection of human cell lines with NYVAC, cells were seeded in DMEM-10 medium (C.1.2) 
either concentrated at 5x105 cells/well in a 6 well reaction plate or at 5x104 in a 24-well flat bottom 
plate. Prior to infection, DMEM-10 was replaced by DMEM medium (C.1.2), the virus was 
homogenized by sonication for 1 min in a Sonifier 450 device (C.4.1) and subsequently mixed on 
a vortex device. 1 h after infection with the desired multiplicity of infection (MOI), unbound and 
loosely attached viruses were removed by stringent washing with 5 x 1 mL PBS. For further 
cultivation DMEM-10 medium was used. 
 
C.5.1.5 Infection of mdDC with NYVAC 
For the infection of mdDC with NYVAC, 5x104 cells/well of 5 d old mdDC were seeded into a 96-
well reaction plate in 100 µl DC-medium (C.1.2). Prior to infection, the virus was homogenized by 
sonication for 1 min in a Sonifier 450 device (C.4.1) and subsequently mixed on a vortex device. 
The cells were infected with the desired MOI in 100 µl DC-medium and incubated for 1 h. 
Unbound and loosely attached viruses were removed by stringent washing with 5 x 1 mL PBS, 
after each washing step cells were pelleted by centrifugation at 500 x g for 5 min at 4 °C. For 
further cultivation, DC-medium was used. 
 
C.5.2 Generation of NYVAC virus stocks 
C.5.2.1 Infection of BHK cells 
NYVAC stocks (C.1.4.3) with high virus titers were generated in baby hamster kidney cells (BHK, 
C.1.1). 2x107 cells were cultivated in a 175 cm2 cell culture flask for 6 h and subsequently infected 
with NYVAC (MOI 0.5 – 3) for 2 h in 15 mL DMEM medium (C.1.2). After removal of the medium, 
the cells were incubated for 48 h in DMEM-10 (C.1.2). 
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C.5.2.2 Virus purification 
To release intracellular viruses, the infected BHK cells (see C.5.2.1) were scraped from the cell 
culture flask and pelleted at 2000 x g for 15 min at 4°C. The cells were resuspended in 1 mL Tris-
HCl (Tris 10 mM, pH 9) and immediately disrupted by three freezing/thawing cycles. After 
sonication for 2 x 2 min with a Sonifier 450 device (C.4.1) cell debris were pelleted at 2000 x g for 
15 min at 4°C. Afterwards, the supernatant was transferred to a new vial, sonicated for 1 x 1 min 
and pelleted again. The supernatants were then combined and diluted in 16 mL Tris-HCl, the 
viruses were concentrated by ultracentrifugation (Optima L-90K, SW32 Ti rotor, Beckman Coulter) 
in a sucrose density gradient (sucrose 45 % w/v, Tris 10 mM, pH 9) twice. For gradient generation 
the sucrose solution was covered with the virus suspension in centrifugation tubes 
(25 mm x 89 mm, Beckman Coulter) and centrifuged for 1 h at 20,000 x g at 4 °C. The virus pellet 
was resolved in 500 µL Tris-HCL, aliquoted and stored at -80 °C. 
 
C.5.2.3 NYVAC titration  
After freezing at -80°C the generated NYVAC stocks (C.1.4.3) were titrated in a plaque forming 
assay. DF-1 cells (C.1.1) were cultivated with a density of 7x105 cells/well in a 6-well plate for 6 h 
in DMEM-10 medium (C.1.2). For infection, the medium was removed and serial dilutions of the 
virus suspension (C.5.2.2) in 400 µL DMEM medium (C.1.2) were incubated on the cells for 1 h. 
The cells were maintained for 2 d with 1 mL DMEM-10. For virus quantification, the viral plaques 
were visualized by staining of the confluent cells for 10 min with crystal violet solution (formol 
25 % (v/v), ethanol 8,5 % (v/v), crystal violet 1.5 g/L). The virus titer was obtained by determining 
the number of plaques considering the dilution factor. 
To analyse NYVAC replication in HeLa cells, 1x105 cells were cultivated in 24-well culture plates. 
For infection, DMEM-10 was exchanged by 100 µL DMEM medium. To analyse NYVAC 
replication in mdDC, 1x105 cells diluted in by 100 µL RPMI1640 medium were disseminated in 24-
well culture plates. The cells were infected with different vaccine candidates at MOI 1 and 
incubated for 1 h. Viruses loosely attached to the cell membrane and present in the supernatant 
were removed six washing cycles with PBS. To analyze time dependency, replication was 
determined in 4 h time periods (up to 24 h). After cultivation, cells and supernatant were sonicated 
for 2 x 2 min with a Sonifier 450 device (C.4.1). For infection the solution was diluted in an 
appropriate amount of DMEM. Further titration was performed as described above. 
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C.5.3 Transgene expression after NYVAC infection and transfection 
The expression rate of different HIV transgenes (C.1.4.3) was determined by p24 staining. HeLa 
cells and mdDC were infected with NYVAC or transfected as described above (C.5.1.3, C.5.1.4 
and C.5.1.5). At indicated time points post infection (h p.i.), the cells were permeabilized, stained 
(C.4.3.2.3) with an anti-p24 antibody (C.1.5.3), and analyzed by FACS analysis (C.4.2.3). 
C.5.4 Maturation of mdDC after NYVAC infection 
The mdDC maturation elicited by infection with NYVAC was determined by analysis of 
upregulation of the maturation markers CD80, CD86 and HLA-DR. mdDC were infected and 
stained as described above (C.5.1.5, C.4.2.3.1 and C.1.5.3). mdDCs, pulsed with LPS (C.1.7) 
served as positive control. 
 
C.5.5 Direct presentation of antigenic peptides on mdDC 
To activate HIV-1 specific CTL by direct presentation, cells were infected with NYVAC (C.1.4.3) 
as described (C.5.1.5). First, the optimal direct presentation time point was evaluated by starting 
the CTL coculture at varying times. For the following experiments, the CTL were cocultivated 4 h 
after mdDC infection. The CTL were thawed and adjusted to a concentration of 5x105 cells/mL in 
RPMI1640-10 (C.1.2) 4 h prior to the coculture start point. Immediately before coculturing, BFA 
was added to the CTL to interrupt the secretion of IFN-γ (C.1.7). After a 12 h coculturing period, 
the cells were harvested and stained in an ICS assay (see C.4.2.2.2) with an anti-IFNγ antibody 
(C.1.5.3). 
 
C.5.6 Cross presentation of antigenic peptides on mdDC 
For determination of the cross presentation potential of the different HIV-1 Gag derived 
transgenes (C.1.3), 5x104 HeLa cells were either transfected with plasmids coding for various HIV 
derived antigens (C.1.5.2) or infected with recombinant NYVACs (C.1.4.3). 100 µL mdDC in a 
concentration of 5x105 cells/mL in RPMI1640-10 (C.1.2) were cocultivated with the HeLa cells 4 h 
post infection. HIV-1 specific CTLs were cocultivated as described before (C.5.6). 
To differentiate between cross presentation mediated by extracellular proteins or infected cells, 
HeLa cells and supernatant were separated 4 h post NYVAC infection by centrifugation for 5 min 
at 500 x g. The coculture with mdDC was performed either with the supernatant or cells resolved 
in 100 µL RPMI1640-10 (C.1.2). After a 12 h coculturing period, the cells were harvested and 
stained in an ICS assay (C.4.2.3.2) with an anti-IFNγ antibody (C.1.5.3). 
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D Results 
D.1 Design of antigens with optimized immunogenicity 
The objective of the EuroVacc foundation was the development of a HIV-1 vaccine that induces 
effective Gag-specific CTL responses. In the phase-I clinical trials EuroVacc01 and EuroVacc02, 
the vaccine candidate NYVAC-C induced only modest Gag, Pol and Nef specific CTL responses 
(see B.2.2.3). 
To enhance immunogenicity, a new generation of antigens based on the immunogen 
97CN54 GPN was developed 256. These new generation antigens were designed to (i) induce 
increased Gag expression, (ii) be accessible for cross presentation and (iii) circumvent 
replacement of Gag epitopes by immunodominant Env, Pol or Nef peptides (see table D.1). To 
realize efficient VLP formation, seven amino acids were substituted in all new generation 
antigens, resulting in an isolate switch from 97CN54 to 97CN001 derived from the same patient. 
The gpn, gag and env genes were RNA and codon optimized by using the GeneOptimizer 
software package (Geneart AG, Regensburg; 249) comprising codon usage adaption and deletion 
of deleterious sequence elements. To realize the required antigen characteristics, the following 
modifications were made: 
 
1. A vaccine variant without gp120 is favoured to avoid immunodominant effects of HIV-Env. 
Secondly, elimination of gp120 circumvents Env-mediated apoptosis and therefore could 
result in enhanced antigen production in transgenic cells 257 [gpn (∆FS, Myr-), see Tab. D.1]. 
2. The reinsertion of a ribosomal frame shift site by reconstitution of the initial codon usage at 
the amino acid positions 1293 to 1345 induces a -1 reading frame switch in 5% of all 
translation events 250. When ribosomal re-positioning occurs, the mRNA is translated 
across the frame shift region resulting in GPN expression. Hence, the frame shift region 
induces translation of Gag and GPN in a ratio of 95:5 leading to an elevated intracellular 
Gag concentration [gpn (FS, Myr-) and gpn (FS, Myr+), see Tab. D.1]. 
3. For enhancing immunogenicity or when applying vector systems not affecting APC, 
efficient induction of T cell responses demands cross presentation. The amount of 
extracellular antigen can be enhanced by utilizing the natively occurring VLP formation of 
HIV-1 Gag molecules (see B.2.2.2). To enable VLP budding, myristoylation of Gag is 
required. To restore the myristoylation acceptor site, the G2A mutation was reverted 
[gpn (FS, Myr+) and gag (Myr+), see Tab. D.1]. The obtained immunogens were shown to 
induce VLP formation efficiently 256. 
4. To enhance Gag-specific T cell responses further, the polnef gene sequence was 
eliminated in some immunogens. The resulting antigens eludes the replacement of 
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Gag-derived peptides by immunodominant PolNef epitopes, but at the expense of a 
minimized number of epitopes in total [gag (Myr-) and gag (Myr+), see Tab. D.1]. 
 
For the generation of vaccine candidates based on the new generation antigens, NYVAC vectors 
were generated. In contrast to the NYVAC-C vaccine, where the gp120 and GPN transgenes are 
controlled a bidirectional E/L promoter, a monodirectional E/L promoter is used in the novel 
vaccine variants. The immunogens and vaccine candidates were developed and kindly provided 
by Dr. Simon Bredl, Dr. Josef Köstler, Katharina Böckl and Dr. Kathrin Kindsmüller (Molecular 
Microbiology and Gene Therapy Unit, Institute of Medical Microbiology and Hygiene, University of 
Regensburg, Head of Department Prof. Dr. Ralf Wagner). The objective of this work was the 
detailed immunological characterization of the novel vaccine candidates in human ex vivo 
systems. The induced Gag expression was analyzed in both, epithelial and dendritic cells (see 
D.2). Furthermore, the immunogen’s influence on DC maturation was analyzed (see D.3). To 
determine the immunogenicity of the resulting new generation vaccine candidates, their ability to 
be presented by direct and cross presentation was examined (see D.4, D.5, D.6 and D.7). 
Additionally, the influence of the delivery system on antigen presentation was determined (see 
D.5). 
 
Tab. D.1 Schematic illustration of immunogen composition, modifications and nomenclature 
Antigen illustration Expressed 
antigens 
VLP 
formation 
Nomenclature 
 
gp120  
GPN 
(equimolar) 
 
Ø 
 
-C 
 
 
GPN (100 %) 
 
Ø 
 
-gpn (∆FS, Myr-) 
 
Gag (95 %) 
GPN (5 %) 
 
Ø 
 
-gpn (FS, Myr-) 
 
Gag (95 %) 
GPN (5 %) 
 
+ 
 
-gpn (FS, Myr+) 
 
 
Gag 
 
Ø 
 
-gag (Myr-) 
 
 
Gag 
 
+ 
 
-gag (Myr+) 
 
 
gp120  
 
-gp120 
 
 
Ø  
 
wt 
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D.2 Antigen expression in NYVAC infected cells 
To enhance their immunogenicity, the new generation antigens were designed for maximal 
expression in infected cells (see D.1). Long lasting immunity and high-level antigen expression 
were believed to be favourable for efficient direct and cross presentation of antigen-derived 
peptides. To determine antigen expression of the different the vaccine candidates, HIV-1 Gag p24 
was quantified in HeLa cells by Western blot and FACS analysis. To determine optimal conditions 
for the cross presentation assay, the influences of virus concentration and incubation time on the 
intracellular Gag-p24 steady-state level were investigated. 
 
D.2.1 HIV-1 Gag based antigens are expressed in large amounts in 
NYVAC infected HeLa cells 
For the development of a vaccine eliciting efficient T cell responses, cross presentation is a 
required feature 141,142. Particularly, when applying vector systems not affecting APC, presentation 
of extracellularly derived antigens is needed for CTL activation. Epithelial cells represent one of 
the cell types that first encounter antigen in a vaccination. Therefore, vaccine-induced immunogen 
expression in epithelial cells represents a source of antigen accessible for presentation on DC. 
For cross presentation assays, the human epithelial tumor cell line HeLa was utilized as a model 
system.  
To determine the influences of (i) possible gp120 cytotoxicity, (ii) reduced GPN expression, (iii) 
VLP formation and (iv) the deletion of PolNef epitopes, infected HeLa cells were analyzed for 
immunogen expression in Western blot and FACS assays.  
 
Due to their potential cytotoxicity the developed immunogens are prone to nonsense mutations. 
Therefore, full-length expression was monitored in a Western-blot analysis. HeLa cells were 
infected at MOI = 5 and incubated for 48 h. Immunogen expression was detected intracellularly. 
Additionally, VLP formation was observed by detection of p55 in the culture supernatants. 
Expression of the artificial 160 kDa GPN polyprotein could be detected in NYVAC-C and NYVAC-
gpn (∆FS, Myr-) infected cells (see Fig. D.1). Obviously, NYVAC-C induced weak immunogen 
expression whereas in NYVAC-gpn (∆FS, Myr-) infected cells, an increased steady-state level of 
GPN was detected. A ribosomal frame shift led to GPN amounts below the limit of detection. 
Immunogen size-reduction by Pol-Nef deletion did not enhance p55 expression in NYVAC-
infected cells. NYVAC-gpn (FS, Myr-) and NYVAC-gpn (FS, Myr+) elicited intracellular steady-
state levels comparable to those induced by NYVAC-gag (Myr-) and NYVAC-gag (Myr+). Budding 
competence reduced the intracellular immunogen amount. Extracellular p55 was detected in the 
supernatant of NYVAC-gpn (FS, Myr+) and NYVAC-gag (Myr+) infected HeLa cells. Surprisingly, 
the budding incompetent Gag (Myr-) immunogen was detected extracellularly 48 h post 
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infection (hpi). The presence of budding incompetent Gag might be caused by the high antigen 
expression levels. Extensive expression in combination with long incubation period -required for 
Western-blot detection – is likely to induce necrosis in the target cells. 
 
A 
                              Cell lysate 
 
 
B 
                              Supernatant    
 
Fig D.1 The vaccine candidates elicit antigen expression in infected HeLa cells 
HeLa cells were infected with different vaccine candidates at MOI 5 and harvested 48 hpi. For 
immunostaining, total cell extracts and concentrated supernatants were prepared. 60 µg of the total protein 
were applied in an SDS-PAGE. The proteins were transferred to a nitrocellulose membrane and detected 
with a primary anti-Gag p55 monoclonal antibody and a secondary goat anti-mouse HRP conjugated 
antibody. A, Detection of intracellular GPN and Gag; B, Detection of GPN and Gag in the supernatant 
 
To further analyze the immunogen expression characteristics, HeLa cells were infected with 
different vaccine candidates by two different concentrations. After incubation for varying time 
periods the cells were stained with an anti-p24 antibody. The target cells were analyzed to 
express the corresponding immunogens by FACS analysis. 
To analyze the infectivity of the different vaccine candidates, the number of p24 positive cells was 
quantified (see Fig. D2). Additionally, the immunogens’ expression levels were analyzed by the 
mean fluorescence intensity (MFI, see Fig. D3 and D4 ).  
In FACS analysis up to 90% of the infected cells were detected to be p24 positive (see Fig. D.2). 
Interestingly, Gag expression could be detected remarkably early. At both low (MOI = 0.5) and 
high (MOI = 5) MOI infections, the antigen was detected intracellularly 4 hpi. The number of p24 
expressing cells did not vary significantly among the vaccine candidates.  
At low MOI infections, after detecting a first expression maximum 4 hpi the intracellular Gag 
amount slightly decreased 6 hpi. When completing the first NYVAC replication cycle within a 
period of 8 - 12 h, p24 expression increased strongly. Although NYVAC replicates poorly in HeLa 
cells, virus-replication resulted in generation of a virus concentration outreaching those primarily 
employed. Due to reinfection with the newly generated NYVACs, an elevated number of p24 
positive cells was detected after one replication cycle 12 hpi.  
Results  43
Due to the superior virus number at high MOI infections, an unsynchronized infection occurred. 
Therefore, the transgene expression course was not influenced by NYVAC replication cycle in 
high MOI infections. 
 
With increasing virus concentrations, variations in the number of p24 positive cells emerged. 
Although NYVAC infectivity is assumed not being influenced by the transgene itself, for some 
vaccine candidates such as NYVAC-gag (Myr-), an increased number of Gag positive cells was 
detected. Due to weak antigen expression induced e.g. by NYVAC-C, in some cells a p24 amount 
below limit of detection can be suggested. Thus, cells expressing a small antigen amount were 
not detected to contain HIV-Gag. Taken together, from an elevated number of p24 positive cells 
an increased Gag expression can be concluded. 
In summary, it was shown that the antigens optimized for Gag expression fulfilled the desired 
requirements. (i) Deletion of gp120, (ii) insertion of an HIV frame shift, and (iii) elimination of 
PolNef resulted in increased number of p24 positive cells. For further discussion, see E.1. 
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Fig. D.2 The amount of HIV-1 p24 expressing HeLa cells is strongly dependent on the vaccine 
candidate concentration (Page 44) 
5x104 HeLa cells were infected by the indicated vaccine candidates, incubated for varying time periods and 
analyzed for intracellular p24 expression by FACS analysis. A. Exemplary histogram illustration of p24 
expression in HeLa cells. The cells were infected at MOI 5 and incubated for 6 h. For comparison, the 
histogram of NYVAC-WT treated cells was overlaid with histograms of cells infected with the different 
vaccine variants. B. and C. Illustration of the time dependency of p24 expression in HeLa cells infected by 
vaccine variants at B. MOI 0.5 and C. MOI 5 
 
MOI 0.5 
MOI 5 
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D.2.1.1 Size-reduced immunogens induce enhanced expression in HeLa cells 
To circumvent epitope competition and cytotoxic effects induced by gp120, vaccine candidates 
not containing gp120 and PolNef were developed. Additionally, it was supposed that 
size-reduction would enhance antigen expression. Compared to NYVAC-C, the size-reduced 
antigens were suggested to elicit an increased antigen expression. Therefore, the intracellular 
Gag amount was quantified by analyzing the mean fluorescence intensity. 
In early infection stages, only slight differences in p24 concentration were observed between the 
vaccine candidates NYVAC-C, NYVAC-gpn (∆FS, Myr-) and NYVAC-gag (Myr-) (see Fig. D.3). As 
expected, deletion of gp120 and PolNef results in an increased p24 antigen expression. Since the 
poxviral replication occurs within 8 hpi to 12 hpi, enhanced p24 levels detected at later timepoints 
of infection give a hint that virus replication occurs.  Nevertheless, virus replication was detected 
to be ineffective in NYVAC-C infected cells (data not shown). Thus, by gp120 deletion an 
increased virus production rate can be achieved resulting in a 2-3 fold increased p24 amount. 
By further deletion of PolNef sequences, the intracellular Gag p24 level can be escalated 
remarkably. Compared to NYVAC-gpn (∆FS, Myr-) infected cells, NYVAC-gag (Myr-) elicits one 
order of magnitude increased antigen expression 12 h post infection. In summary, size reduction 
as well as elimination of gp120 resulted in a strongly enhanced Gag expression. 
 
A 
                                MOI 0.5 
B 
                                   MOI 5 
 
Fig. D.3 Deletion of HIV-1 gp120 and PolNef increases p24 expression after one NYVAC replication 
cycle 
To determine the influence of epitope minimization on immunogen expression, 5x104 HeLa cells were 
infected either by NYVAC-C or NYVAC-gpn (∆FS, Myr-) and analyzed at the indicated times post infection 
for intracellular p24 expression by FACS analysis. Illustration of the time dependency of p24 expression in 
HeLa cells infected by vaccine variants at A. MOI = 0.5 and B. MOI = 5 
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D.2.1.2   The insertion of the natural frameshift in the GPN polyprotein results in increased 
HIV-1 Gag expression 
To achieve enhanced Gag expression without affecting epitope presence, a ribosomal frame shift 
was introduced into the GPN polyprotein. This modification was described to result in Gag:GPN 
expression in a ratio of 95:5 250. To observe the influence of the naturally occurring ribosomal 
frame shift on antigen expression, the intracellular p24 amount in vaccine candidate infected 
HeLa cells was analyzed. 
When comparing NYVAC-gpn (∆FS, Myr-) and NYVAC-gpn (FS, Myr-), a 3 to 4-fold increased p24 
steady-state level was observed for the immunogens with frame shift 12 hpi (see Fig. D.4). As 
expected, the ribosomal frameshift induces a strong increase in p24 amount. Thus, introduction of 
a -1 frame shift by reconstitution of the initial codon usage at the amino acid positions 1293 to 
1345, the Gag expression was enhanced without affecting epitope presence. 
 
A 
                                 MOI 0.5 
B 
                                   MOI 5 
 
Fig. D.4 A frame shift insertion in the GPN polyprotein leads to increased intracellular p24 amounts 
To determine the influence of a ribosomal frame shift on immunogen expression, 5x104 HeLa cells were 
infected by either NYVAC-gpn (∆FS, Myr-) or NYVAC-gpn (FS, Myr-) and analyzed at the indicated times 
post infection for intracellular p24 expression by FACS analysis. Illustration of the time dependency of p24 
expression in HeLa cells infected by vaccine variants at A. MOI = 0.5 and B. MOI = 5 
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D.2.1.3   Myristoylation of Gag diminishes the intracellular Gag steady-state levels due to 
budding  effects 
For efficient cross presentation, the immunogen has to be available extracellularly in sufficient 
amounts. The ability of Gag to form VLP was described to facilitate cross presentation 234,235. Due 
to a translational block of late poxviral genes in APC, cross presentation is necessary when using 
NYVAC as vaccine delivery system. VLP budding requires efficient membrane anchoring. 
Therefore, HIV-1 Gag has to be myristoylated posttranslationally. An altered myristoylation site 
was described to inhibit VLP formation efficiently 19.  
To observe the impact of budding on the intracellular Gag amount, p24 was quantified in vaccine 
candidate infected HeLa cells (see Fig. D.5). As detected in Western-blot analysis (see Fig. D.1) 
when comparing NYVAC-gag (Myr-) with NYVAC-gag (Myr+), a 5-fold increase of intracellular p24 
concentration was observed 12 h post infection. NYVAC-gpn (FS, Myr+) infected cells contain a 
3-fold decreased Gag amount compared to NYVAC-gpn (FS, Myr-) infected cells. Hence, 
inhibition of p55 VLP formation resulted in an intracellular Gag accumulation. Again, the MOI 
strongly influenced the transgene expression levels. A 10-fold increased virus multiplicity induced 
an almost 3-fold increased Gag concentration. Nevertheless, antigen expression did not increase 
in a linear manner compared to the applied virus concentration. Thus, a limitation of transgene 
expression is suggested. 
 
A 
                               MOI 0.5 
B 
                                   MOI 5 
Fig. D.5 VLP formation evoked by HIV-1 Gag myristoylation leads to decreased intracellular p24 
amounts 
To determine the influence of VLP budding on immunogen expression, 5x104 HeLa cells were infected by 
NYVAC coding either for HIV-1 antigens with intact or mutated Gag myristoylation site. After incubation, the 
cells were analyzed at the indicated times post infection for intracellular p24 expression by FACS analysis. 
Illustration of the time dependency of p24 expression in HeLa cells infected by vaccine variants at 
A. MOI = 0.5 and B. MOI = 5 
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D.2.2 HIV-1 Gag based immunogens could be detected in low amounts 
in NYVAC infected mdDC 
Although antigen cross presentation is described to be sufficient for the generation of CTL based 
immunity induced by vaccination, direct presentation could complement or enhance vaccine 
induced immunity 121. Due to their localization in epidermal tissues, Langerhans cells (LDC) 
represent an APC population that is a key player in generating vaccine induced immunity. 
Vaccines based on viral vector systems can enter the APCs’ cytoplasm either by infection 
mediated by receptor mediated endocytosis. Therefore, to achieve direct presentation, the antigen 
delivery system has to infect DC such as LDC productively. Poxviral vector systems were 
described to infect APC only slightly resulting in poor antigen expression (see B.3). Nevertheless, 
the vaccine candidates were observed whether they infect mdDC directly. 
To analyze the immunogen expression characteristics in APCs, mdDCs cells were infected with 
different vaccine candidates by two different concentrations. After incubation for varying time 
periods the cells were stained with an anti-p24 antibody. The target cells were analyzed to 
express the corresponding immunogens by FACS analysis. 
NYVAC uptake as well as an efficient antigen expression could be detected in mdDC (see Fig. 
D.6). As described for HeLa cells (see D.2.1) a strong influence of the virus concentration on the 
ratio of p24+ cells was observed. HIV-1 Gag was analyzed to be expressed within few hours post 
infection. At low MOI infections, up to 18% p24 positive cells were quantified (see Fig. D.6 B). In 
contrast to transduced HeLa cells, no decline in transgene expression was observed for most of 
the vaccine candidates. 
Again, VLP formation induced a decline in the number of p24+ cells. Notably, the size-reduced 
vaccine candidate NYVAC-gag (Myr-) did not induce increased p24 expression compared to 
NYVAC-gpn (ΔFS, Myr-) and NYVAC-gpn (FS, Myr-). 
Infection with high virus multiplicities resulted in increased intracellular Gag concentrations. 
Almost 40 % of the employed cells were detected to contain p24 (see Fig. D.6 C). Expression was 
shown to peak at 8 hpi.  
Consistent with the results obtained for HeLa cells, the NYVAC-gag (Myr-) vaccine candidate 
coding for the size-reduced immunogen induced strongest antigen expression. Immunogen 
enriched vaccine candidates such as NYVAC-gpn (ΔFS, Myr-) elicited low Gag content in mdDCs. 
Infection with the gp120 containing NYVAC-C variant led to a complete loss of Gag expression 
8 hpi independently of the applied MOI.  
Compared to infection of HeLa cells, immunogen expression in mdDC was shown to be less 
productive. Especially at later time points, a lower number of Gag containing cells were detected. 
These results are consistent with published data, which show that NYVAC replication is limited in 
mdDC (see B.1.3.4).  
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Fig. D.6 The expression of HIV-1 p24 in NYVAC infected mdDCs cells is strongly dependent on the MOI  
5x104 mdDCs were infected by the indicated vaccine candidates, incubated for varying time periods and 
analyzed for intracellular p24 expression by FACS analysis. A. Exemplary histogram illustration of p24 
expression in mdDC. The cells were infected at MOI 5 and incubated for 6 h. For comparison, the histogram 
of NYVAC-WT treated cells was overlaid with histograms of cells infected with the different vaccine variants. 
B. and C. Illustration of the time dependency of p24 expression in mdDCs infected by vaccine variants at B. 
MOI 0.5 and C. MOI 5 
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D.2.2.1   Myristoylation of Gag diminishes the intracellular Gag amounts slightly whereas 
immunogen minimization has no influence on the antigen expression in mdDC 
To further observe the influence of immunogen design on expression in mdDC, Gag levels were 
quantified in mdDC infected with different vaccine candidates. For HeLa cells it was shown that 
introduction of a ribosomal frame shift boosted antigen expression (see D.2.1.2) whereas VLP 
formation diminished the intracellular p24 amount strongly (see D.2.1.3). Since infected DCs are 
shown to suppress expression of late viral genes partially 79,83, only modest immunogen 
expression was detected. Thus, p24 detection 12 hpi is exemplary illustrated (Fig. D.7). 
Nevertheless, despite the long incubation period, the vaccine candidates induce only slight 
immunogen expression. 
In contrast to vaccine candidate infected HeLa cells, mdDC infected with NYVAC-gpn (FS, Myr-) 
did not express increased Gag amounts compared to NYVAC-gpn (ΔFS, Myr-). The intracellular 
p24 concentration was shown not to differ between both variants (see Fig. D.7). This indicates 
that in mdDC, a transcriptional or translational limitation masks different immunogen expression 
capacities that were observed for HeLa cells.  
In NYVAC-gag (Myr-) infected mdDC, an increased p24 steady-state level was detected 
compared to NYVAC-gag (Myr+) targeted cells. Certainly, in mdDC the observed differences 
between both vaccine candidates are less distinct than in HeLa cells. Due to limited immunogen 
expression in mdDC, NYVAC-gag (Myr-) / NYVAC-gpn (FS, Myr-) only induced a slightly 
increased p24 amount compared to NYVAC-gag (Myr+) / (FS, Myr+). 
 
A B 
Fig. D.7 The insertion of the natural HIV frameshift in the GPN polyprotein has no effect on p24 
expression while VLP budding reduces the intracellular p24 content in mdDCs slightly 
5x104 mdDCs were infected by the indicated vaccine candidates at MOI 5, incubated for varying time 
periods and analyzed for intracellular p24 expression by FACS analysis. A. Illustration of the influence of 
frame shift reconstitution in the artificial GPN polyprotein on intracellular p24 amount in mdDCs infected with 
the indicated vaccine candidates. B. Illustration of the impact of VLP formation on the intracellular p24 
amount in mdDCs infected with the indicated vaccine candidates. 
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D.3 NYVAC elicits a poor maturation effect of mdDC 
Professional APCs such as DC are the only cell types that are able to translate innate into 
adaptive immune responses. APC can capture immunogens and process them into peptides, 
which are presented on the cell surface. Antigen presentation can initiate cellular immune 
responses. For efficient T cell stimulation, naïve APC alter their phenotype by upregulation of 
distinct molecules. This maturation process comprises upregulation of (i) antigen presenting HLA 
complexes, (ii) co-stimulatory molecules such as CD80 and CD86 and (iii) chemokine receptors 
that mediate migration to lymph nodes (see B.2.2.1). Maturation can be driven by bacterial 
antigens (e.g. LPS), inflammatory cytokines, ligands of surface receptors (e.g. CD40), or viral 
products. Although NYVAC was shown to induce only incomplete DC maturation due to immune 
escape mechanisms, efficient T cell priming was observed in vaccination studies (see B.3).  
Since DC maturation is essential for T cell stimulation, the vaccine candidates were analyzed 
concerning their DC activation capacity. Besides the stimulation induced by the viral vector 
backbone, the immunogen’s influence on DC maturation was determined. For detailed analysis of 
the DC activation potential, the vaccine candidate-driven upregulation of several maturation 
markers was observed. Besides the antigen presenting HLA class-II protein HLA-DR, 
upregulation of the co-stimulatory molecules CD80 and CD86 was evaluated. For analysis, mdDC 
were infected with the vaccine candidates by two different MOI. After several time periods the 
surface markers were detected by specific antibodies. The cells were analyzed to express the 
corresponding maturation markers by FACS analysis. 
As described by Guerra et al. 79, NYVAC infected mdDC were shown to maturate incompletely 
(see Fig. D.8). The co-stimulatory molecules CD80 and CD86 (also known as B7-1 and B7-2) 
were not upregulated during the maturation process. Remarkably, the level of CD80 and CD86 
positive cells declined between 24 hpi and 48 hpi, which was not observed for LPS stimulated 
cells. Virus multiplicity did not influence mdDC maturation (see Fig. D.8 B-E). 
The antigen presenting HLA class-II molecule HLA-DR was shown to be upregulated in NYVAC 
infected DC (see Fig. D.8 F and G). HLA-DR upregulation was observed 12 hpi, whereas the 
maximal surface concentration was achieved 24 h post infection. As monitored for CD80 and 
CD86, the number of HLA-DR positive cells declined 48 h after NYVAC infection. At increased 
NYVAC multiplicities, upregulation of HLA-DR was enhanced slightly. 
Altogether, no significant differences between the varying vaccine candidates were detected 24 h 
after DC infection. A decreased maturation marker amount on the cell surface 48 h post infection 
was detected for all candidate vaccines except NYVAC-gpn (ΔFS, Myr-). Thus, in the case of the 
developed vaccine candidates the immunogens play only a minor role in inducing DC maturation.  
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Fig. 8 is continued on page 53 
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                     CD80 MOI 5 
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                   HLA-DR MOI 0.5 
G 
                    HLA-DR MOI 5 
Fig. D.8 NYVAC but not HIV-1 derived immunogens induce partial mdDC maturation  
5x104 mdDCs were infected by different vaccine candidates at the indicated MOI, incubated for different 
time periods and analyzed for maturation marker expression by FACS analysis A. Exemplary histogram 
illustration of quantifying maturation markers on mdDCs. The cells were infected at MOI = 5 and incubated 
for 24 h. For comparison, the histogram of untreated mdDCs was overlaid with histograms of cells infected 
with the different vaccine candidates. B. to G, Determination of the time dependency of maturation marker 
presentation on mdDCs infected with the different vaccine candidates at MOI 0.5 or 5.  
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D.4 The HIV-1 Gag-derived peptide GL9 can effectively be 
presented directly on vaccine-infected mdDC  
Direct presentation of antigen derived peptides is required for the generation of immune 
responses directed against intracellular pathogens or antigens. Therefore, an efficient vaccine is 
required to induce both transgene expression as well as maturation of DC present at vaccination 
sites. The engineered new generation antigens were analyzed for their ability to be processed into 
peptides that subsequently are presented on the APC surface by direct presentation. Additionally, 
the vaccine induced mdDC maturation was demonstrated to be sufficient for T cell restimulation. 
For restimulation assays, a Gag specific CD8+ cytotoxic T cell clone isolated from an HIV infected 
donor was utilized. The CTL clone expresses a TCR that specifically binds to the HIV-1 Gag 
p24-derived peptide GPGHKARVL (GL9) in complex with an HLA-B*07 molecule. Recognition of 
a sufficient amount of GL9-HLA-B*07 pMHC complexes as well as co-stimulatory molecules 
induces CTL restimulation resulting in IFN-γ release. By inhibiting ER-mediated export with 
Brefeldin A, IFN-γ expression can be detected by ICS staining and FACS analysis. mdDC were 
generated from monocytes derived from HLA-B*07 positive donors. To analyze the immunogens’ 
capacity to be presented on APC, the influences of (i) incubation time and (ii) virus concentration 
on direct presentation were evaluated.  
 
(i) To determine the optimal timepoint between peptide presentation and maturation, the 
co-culture of NYVAC-infected mdDC with GL9-specific CTL was started at varying 
timepoints.  
(ii) The influence of virus multiplicity on direct presentation was analyzed at the optimal 
cocultivation conditions defined previously. 
The experimental layout of the direct presentation assay is illustrated in Fig. D.9. 
 
 
Fig. D.9 Experimental layout of the direct presentation assays 
For direct presentation analysis, mdDC derived from a HLA-B*07+ donor were infected with the vaccine 
candidates at (i) defined or (ii) varying virus multiplicities. After incubation for (i) varying time points or (ii) 
6 h, the mdDC were cocultivated with an equal amount of a GL9-specific T cell clone. After an incubation 
period of 12 h, the T cells were evaluated to express IFN-γ by FACS analysis.  
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For FACS analysis, T lymphocytes were detected by analysis of size (FSC) and inner complexity 
(SSC, see Fig. D.10 A). CTL were identified by staining with a CD8 specific antibody (see Fig. 
D.10 B). CD8+ cells were analyzed for IFN-γ expression by ICS. Peptide-pulsed mdDC represent 
the positive control (see Fig. D.10 B). 
 
A                                      B 
 
Fig. D.10 Population determination in FACS analysis of direct presentation assays 
A. Illustration of the population distribution between CTLs and mdDCs in a direct presentation assay. The 
cocultivated HLA-B*07 mdDC and CTL were gated by analysis of cell volume (FSC) and inner complexity 
(SSC) at which the gate coloured in red corresponds to T lymphocytes. B, T lymphocytes were determined 
to express CD8 in a surface staining. In addition, an ICS of IFN-γ was performed. For calibration purposes, 
an unstained control was analyzed. To control proper gating, unstimulated as well as GL9 peptide 
stimulated CTLs were detected.  
 
 
D.4.1 Direct presentation of the HIV-1 Gag derived GL9 peptide is 
strongly influenced by the immunogen characteristics 
As shown, transgene expression and maturation of vaccine candidate infected mdDC was 
induced modestly (see 2.3.2 and D.4). Despite those low levels of intracellularly detected 
antigens, direct presentation of Gag-derived peptides was analyzed in an in vitro asay.  
Surprisingly, despite low expression levels in infected mdDC, the vaccine variants coding for the 
GPN polyprotein were shown to induce the most extensive GL9 CTL restimulation (see Fig. D.11 
and D.12 A and B). Although NYVAC-gpn (ΔFS, Myr-) induced more extensive immunogen 
expression in mdDC compared to NYVAC-C (see Fig. D.1) both vaccine candidates stimulated 
high numbers of Gag specific CTLs. At low MOI infections (MOI 0.5) 14-18% of the applied 
T lymphocytes became activated (see Fig. D.11 B). Infection with an increased multiplicity (MOI 
5), led to a CTL restimulation rate of  37 - 42% (see Fig. D.11 C). 
Interestingly, peptide presentation induced by the new generation immunogens was reduced 
strongly in spite of increased expression levels. Compared to GPN (FS-), GL9 direct presentation 
of the GPN (FS+) immunogen was decreased 5 to 10-fold dependent on the MOI (see D.12 A and 
B).  
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When infecting with high virus multiplicities, elimination of PN recovered the peptide presentation 
to some extent. NYVAC-gag (Myr-) and NYVAC-gag (Myr+) infected mdDC were capable of 
restimulating 23 and 15 % of the applied T lymphocytes, respectively (see Fig. D.12 C and D). As 
shown, VLP formation diminishes intracellular Gag concentration (see D.3.2.1 and D.3.1.3). 
Consequently, budding competence results in reduced peptide presentation in Gag (Myr+) 
transgenic cells. Slight differences can be observed between NYVAC-gpn (FS, Myr-) and 
NYVAC-gpn (FS, Myr+) infected mdDC (see Fig. D.12 C and D). 
  
Remarkably, CTL stimulation by direct presentation was indeed achieved subsequently after 
NYVAC infection. This suggests that (i) NYVAC uptake, (ii) transgene expression and 
proteasomal digestion as well as (iii) presentation occurred within a minimal interval of 4 hpi. At 
low MOI infections, no decline in antigen presentation was observed (see Fig. D.11 B). This 
indicates, that the GL9 peptide was presented over an at least 12 h time-period as measured by 
the CTL restimulation capacity. When infecting with high virus amounts, the most extensive CTL 
restimulation was detected 6 h post infection (see Fig. D.11 C). Summing up, the new generation 
vaccine candidates require administration at high MOI, which results in necrosis of the target 
cells. Necrotic cells can stimulate immune responses via cross presentation but do not participate 
in direct presentation 258. 
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Fig. D.11 GL9 presentation by NYVAC infected mdDCs is strongly dependent on immunogen 
characteristics and the applied virus amount 
5x104 mdDC were infected with different vaccine candidates, incubated for the indicated periods and 
cocultivated with GL9 CTLs. CD8+ CTLs were investigated for IFN-γ expression by FACS analysis. 
A. Exemplary dot plot illustration of GL9 CTL restimulation by mdDCs infected with the indicated vaccine 
candidates. The cells were infected at MOI 5 and incubated for 6 h. T lymphocytes were analyzed for 
expression of both CD8 and IFN-γ. B. and C. Illustration of the time dependency of CTL restimulation by 
direct presentation. mdDCs were infected with the indicated vaccine candidates at B. MOI 0.5 and C. MOI 5. 
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Fig. D.12 Frame shift insertion as well as VLP formation influence direct presentation of the 
Gag-derived GL9 peptide 
5x104 mdDC were infected with the indicated vaccine candidates, incubated for varying periods and 
cocultivated with GL9 CTLs. CD8+ CTLs were investigated for IFN-γ expression by FACS analysis A. and B. 
Illustration of the influence of frame shift insertion into the artificial GPN polyprotein on GL9 direct 
presentation on mdDCs. mdDC were infected by vaccine variants at A. MOI 0.5 and B. MOI 5. C. and D. 
Illustration of the influence of VLP formation on on GL9 direct presentation on mdDCs. The cells were 
infected with vaccine variants at C. MOI 0.5 and D. MOI 5. 
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D.4.2  The direct presentation efficiency is strongly dependent on the 
NYVAC concentration 
In direct presentation, a strong dependency on virus multiplicity can be observed (see D.4.1). The 
ability of some antigens to be directly presented on mdDC strongly depends on the virus amount 
(see Fig. D.10). To analyze the influence of the NYVAC concentrations further, mdDC were 
infected with a set of virus multiplicities. Direct presentation was determined 6 h post infection by 
co-cultivation of a GL9 specific T cell clone. 
Again, the most extensive GL9 CTL restimulation was induced by the artificial GPN polyprotein 
(see Fig. D.13). mdDC infection with NYVAC-gpn (ΔFS, Myr-) and NYVAC-C at MOI 0.1 was 
sufficient to mediate activation of considerable CTL numbers. For both vaccines, maximal CTL 
restimulation was observed when infecting mdDC with MOI > 1. The CTL activation potential of 
the remaining vaccine candidates was increased in an almost linear manner again being highest 
at MOI 1 to 2. Compared to NYVAC-gpn (ΔFS, Myr-) and NYVAC-C, GL9 presentation was 
observed to be less extensive despite enhanced immunogen expression.  
When exceeding virus multiplicities of 10, a strong decline in direct presentation was detected for 
all vaccine candidates. Infections with high NYVAC concentrations induce necrosis. As described, 
necrotic cells can stimulate immune responses via cross presentation but do not participate in 
direct presentation 258. This indicates that the vaccines have to be administered in well-defined 
and accurate amounts. Low virus multiplicities are not sufficient to activate large numbers of CTL 
whereas over-concentration aborts direct presentation of the GL9 peptide.  
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Fig. D.13: Efficient GL9 direct presentation requires a well balanced NYVAC multiplicity 
5x104 mdDC were infected with the indicted vaccine candidates at varying MOI, incubated for 6 h and 
cocultivated with an equal amount of GL9 CTLs. CD8+ CTLs were analyzed for IFN-γ expression by FACS 
analysis. A. and B. Exemplary dot plot illustration of GL9 CTL restimulation by vaccine infected mdDC. The 
cells were infected with the indicated vaccine candidates and incubated for 6 h. T lymphocytes were 
analyzed to express both CD8 and IFN-γ. mdDC were infected by vaccine variants at A. MOI 0.3 and B. 
MOI 3. C. Illustration of the restimulation of CD8+ cells dependent on virus multiplicity in a direct 
presentation assay. 
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D.5 The HIV-1 Gag-derived GL9 peptide can be presented on         
NYVAC infected mdDC by cross presentation 
When administering vaccines by intramuscular injection, mainly cells other than APC such as 
fibroblast or epithelial cells are targeted by the vaccine. Professional APC can take up cells, cell 
debris and extracellular antigens. Therefore, proteins expressed in tissue cells represent a source 
of immunogens allowing T lymphocyte activation. Extracellular proteins are endocytosed and 
degraded. Peptides derived from extracellular proteins are mainly not targeted to MHC class-I 
compartments but are presented on MHC class-II molecules 124,125. By cross presentation, these 
peptides can be presented on MHC-class-I molecules. The ability to be cross presented on MHC 
class-I molecules strongly depend on the antigen design (see B.2.1). In generating T cell 
immunity, cross presentation can support the direct presentation pathway. For poxviral vector 
systems, cross presentation was described to be the major mode of inducing CTL responses 142.  
To analyze the new generation antigen’s cross presentation capacity, vaccine candidate infected 
cells were evaluated for induction peptide presentation on mdDC. As a model system, the human 
epithelial tumor cell line HeLa was utilized for cross presentation assays. NYVAC infected HeLa 
cells were shown to express the Gag-derived transgenes efficiently (see D.3.1). As described for 
direct presentation assays, the HIV-1 GL9 specific CTL clone was applied for the detection of 
cross presentation. Again, the (i) time dependency of cross presentation and (ii) the influence of 
the virus concentration were evaluated. To avoid direct mdDC infection, viruses loosely attached 
on HeLa cells or present in the supernatant were eliminated by multiple washing steps. By 
washing the virus concentration in the supernatant was reduced 200-fold (data not shown). Since 
NYVAC was found to replicate in HeLa cells, mdDC infection with virus progenitors derived from 
infected cells has to be excluded. Therefore, the cross presentation assay was developed not to 
exceed a duration of 8 h until CTL cocultivation was initiated. 
 
(i) To determine the optimal timepoint for cocultivation of NYVAC-infected HeLa cells with 
mdDC. the coculture was initiated at varying timepoints.  
(ii) The influence of virus multiplicity on cross presentation was analyzed adopting the optimal 
cocultivation conditions defined previously. 
 
The experimental layout of the cross presentation assay is illustrated in Fig. D.14. 
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Fig. D.14 Experimental layout of cross presentation assays 
For cross presentation analysis, HeLa cells were infected with the vaccine candidates by (i) MOI 5 or (ii) 
varying virus multiplicities. After removal of extracellular viruses by 5 washing steps 1 h post infection cells 
were incubated for 3 h. After incubation the HeLa cells were cocultivated with mdDC derived from a HLA-
B*07+ donor. After incubation for (i) varying time points or (ii) 4 h, the mdDC were cocultivated with an equal 
amount of a GL9-specific T cell clone. After an incubation period of 12 h, the T cells were evaluated to 
express IFN-γ by FACS analysis.  
 
GL9-CTL restimulation was determined by FACS analysis. T lymphocytes were detected by 
analysis of size (FSC) and inner complexity (SSC, see Fig. D.10 A). CTL were identified by 
staining with an antibody directed against the CD8 receptor (see Fig. D.10 B). CD8+ cells were 
analyzed for IFN-γ expression by ICS. Peptide-pulsed mdDC represent the positive control (see 
Fig. D.10 B). 
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Fig. D.15 Population determination in FACS analysis of cross presentation assays 
A. Illustration of the population distribution between CTLs and mdDCs in a cross presentation assay. The 
cocultivated HeLa cells, HLA-B*07 mdDC and CTL were gated by analysis of cell volume (FSC) and inner 
complexity (SSC) at which the gate coloured in red corresponds to T lymphocytes. B, T lymphocytes were 
determined to express CD8 in a surface staining. In addition, an ICS of IFN-γ was performed. For calibration 
purposes, an unstained control was analyzed. To control proper gating, unstimulated as well as GL9 peptide 
stimulated CTLs were detected.  
 
D.5.1 The design of HIV-1 Gag derived antigens influences the capacity 
of the GL9 peptide to be cross presented  
As detected for direct presentation, peptide cross presentation was not influenced by modest 
immunogen expression levels (Fig. D.16). Peptide presentation on mdDC occurred within a time 
period of 4 – 6 h post cocultivation initiation with infected HeLa cells. NYVAC-variants that 
initiated enhanced antigen expression in HeLa cells (see Fig. D.3 to D.5) did not induce cross 
presentation when being administered at MOI 5 (see Fig. D.16). Only NYVAC-gpn (ΔFS, Myr-) 
and NYVAC-C, both encoding for the artificial GPN polyprotein, were shown to induce the GL9 
CTL restimulation by cross presentation. Remarkably, NYVAC-C elicited a 4-fold higher CTL 
activation rate compared to NYVAC-gpn (ΔFS, Myr-). Despite an increased Gag steady-state level 
in HeLa cells, introduction of a ribosomal frame shift strongly reduced the immunogen’s cross 
presentation capacity (see Fig. D.4 and D.17 A). Due to their ability to form VLP, budding 
competent immunogens were designed to induce cross presentation. Surprisingly, peptides 
derived from budding competent antigens were not presented on mdDC (see Fig. D.17 B).  
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Fig. D.16 Vaccine candidate infected HeLa cells are capable of inducing GL9 cross presentation 
5x104 HeLa cells were infected with the indicated vaccine candidates at MOI 5, incubated for 4 h and 
cocultivated with an equal number of mdDCs. Cocultivation with GL9 CTLs was initiated at the indicated 
time points. After a 10 h cocultivation period, CD8+ CTLs were analyzed for IFN-γ expression by FACS 
analysis. A. Exemplary dot plot illustration of GL9 CTL restimulation by mdDC cocultivated for 6 h with 
vaccine candidate-infected HeLa cells B. Illustration CD8+/IFN-γ+ cells restimulation by mdDC cocultivated 
for the indicated time points with vaccine candidate-infected HeLa cells. 
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Fig. D.17: Cross presentation of GL9 is strongly influenced by immunogen composition and occurs 
within few hours post cocultivation 
5x104 HeLa cells were infected with the indicated vaccine candidates at MOI 5, incubated for 4 h and 
cocultivated with an equal number of mdDCs. Cocultivation with GL9 CTLs was initiated at the indicated 
time points. After a 10 h incubation period, CD8+ CTLs were analyzed for IFN-γ expression by FACS 
analysis. A. and B.  Detailed illustrations of CD8+/IFN-γ+ GL9 CTL activation induced by selected vaccine 
candidate subsets.  
 
D.5.2   The cross presentation efficiency of Gag derived peptides is 
strongly dependent on the MOI  
In direct presentation assays, a strong dependency on virus multiplicity was observed (see D.4.2). 
Due to the marginal cross presentation capacity observed for some vaccine candidates, the effect 
of virus concentration on the magnitude of cross presentation was examined. When administering 
the vaccines at MOI > 10, an up to 10-fold increase in CTL restimulation was detected (see 
Fig. D.15). Similar to direct presentation, NYVAC-gpn (ΔFS, Myr-) and NYVAC-C coding for GPN 
induced the most extensive CTL activation. The restricted cross presentation capacity of 
NYVAC-gag (Myr-) could be circumvented by application of higher virus concentrations whereas 
the remaining antigens failed to induce considerable CTL restimulation even at highest MOIs 
tested.  
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Fig. D.18: GL9 cross presentation requires vaccine candidate application in high concentrations 
5x104 HeLa cells were infected with different vaccine candidates at the indicated MOIs, incubated for 4 h 
and cocultivated with mdDCs. Cocultivation with GL9 CTLs was initiated 4 h post HeLa / mdDC coculture 
initiation. After a 10 h incubation period, CD8+ CTLs were analyzed to express IFN-γ by FACS analysis. A. 
and B. Exemplary dot plot illustration of GL9 CTL restimulation by mdDC infected by vaccine candidate 
infected HeLa cells. The cells were infected and incubated for 4 h each. T lymphocytes were analyzed to 
express both CD8 and IFN-γ. C. Illustration of CD8+ GL9 CTL restimulation dependend on the virus 
multiplicity in a cross presentation assay. 
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D.5.3  The cross presentation of Gag derived peptides can effectively 
be driven by transfected HeLa cells and is not influenced the 
NYVAC vector 
Based on the results obtained in the clinical phase-I studies EuroVacc01/02, the new generation 
antigens were designed in consideration of maximizing Gag accessibility. However, in direct and 
cross presentation assays the newly designed immunogens did not fulfil the desired 
characteristics. To determine whether the NYVAC-vector itself has an influence on cross 
presentation, an alternative immunogen delivery agent was tested. As a vector system, the DNA 
plasmid pcDNA3.1 was chosen. DNA vectors eliminate the peptide replacement induced by 
vector-own peptides. Since the monodirectional CMV promoter does not allow expression of two 
separate antigens, NYVAC-C encoding for gp120 and GPN can not be mimicked by pcDNA3.1. 
To allow comparison, infection and transfection rates of HeLa cells are required to be similar. 
Preliminary experiments demonstrated that a transfection rate of 90 % was achieved when 
transfecting 1x105 HeLa cells with 1µg plasmid DNA. This corresponds to the infections levels 
obtained with NYVAC infection (see Fig. D2).  
Consistent with the results shown above (see D.5.2), only the artificial polyprotein GPN was able 
to induce efficient cross presentation (see Fig. D.18). Cross presentation of GPN-derived GL9 
peptides induced restimulation of approximately 6 % of the applied CTL. Modest GL9 presentation 
driven by pcDNA3.1-gpn (FS, Myr-) transfected HeLa cells was observed. The remaining 
candidate vaccines did not induce CTL restimulation. Again, VLP formation capacity did not elicit 
cross presentation. Peptide presentation was observed to occur subsequently after plasmid DNA 
transfection. As shown for the NYVAC vector, GL9 presentation is declined 8 h post transfection. 
Thus, the obtained results mostly correspond to the conclusions drawn from the cross 
presentation assays driven by NYVAC infected HeLa cells. 
 
Contents  68
 
 
Fig. D.19 Experimental layout of cross presentation assays applying transfected HeLa cells 
1x105 HeLa cells were transfected by 1 µg pcDNA3.1 coding for different HIV-1 derived antigens. The cells 
were incubated for 4 h. After incubation the HeLa cells were cocultivated with mdDC derived from a 
HLA-B*07+ donor. After incubation for varying time points, the mdDC were cocultivated with an equal 
amount of a GL9-specific T cell clone. After an incubation period of 12 h, the T cells were evaluated to 
express IFN-γ by FACS analysis.  
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Fig. D.20 HeLa cells transfected with pcDNA3.1-gpn (ΔFS, Myr -) induce most extensive GL9 cross  
presentation in mdDC 
1*105 HeLa cells were transfected with 1 µg pcDNA3.1 coding for the indicated immunogens. The cells were 
incubated for 4 h and cocultivated with mdDCs for the indicated timepoints, subsequently followed by GL9 
CTL cocultivation. The cells were incubated for 10 h. CD8+ CTL were analyzed for IFN-γ expression by 
FACS analysis. A. Exemplary dot plot illustration of GL9 CTL restimulation driven by transfected HeLa cells. 
The cells were cocultivated with mdDC for a 4 h time period. After cocultivation, CTL were analyzed for IFN-
γ expression. B. Illustration of CD8+ GL9 CTL restimulation in a cross presentation assay dependent on the 
indicated HeLa – mdDC coculture incubation periods. 
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D.6 Cross presentation of the HIV-1 Gag-derived GL9 peptide 
is mainly driven by the uptake of cell-associated 
immunogens  
For the induction of cross presentation, besides the protein half-life and amino acid sequence 
(see B.2.2.3), the accessibility of extracellular immunogens is described to be a limiting 
parameter 129. The ability of Gag to form VLPs increases the amounts of extracellular immunogen 
that is available for cross presentation. VLPs consist of a lattice of immature Gag precursors 
surrounded by a host cell derived membrane and are able to self assemble into an organized 
particle structure. These particles represent a form of subunits vaccines that can efficiently induce 
cross priming 232,233,259. Therefore, candidate vaccines able to induce VLP formation were 
developed. Surprisingly, in cross presentation assays these vaccine variants were shown not to 
elicit GL9 CTL restimulation. As described, phagocytosis of cell bodies derived from apoptotic 
cells was reported to trigger cross presentation 136,137. Therefore, uptake and presentation of 
immunogens associated with cells or embedded in VLP was compared. 
To analyze whether cross presentation is driven by either infected cells or VLP containing 
supernatants, both fractions were analyzed in a cross presentation assay separately (see 
Fig. D.21). HeLa cells were infected by the vaccine candidates at MOI 5. After virus removal 1 h 
post infection, cells were incubated for 3 h. The VLP containing supernatant was removed and 
both, HeLa cells and supernatant, were incubated on mdDC for 4 h. To detect cross presentation, 
the mdDC were co-cultivated with anti-GL9 CTL.  
As described for influenza 104,138, DCs infected with infected HeLa cells were capable of 
stimulating specific CTL. As shown previously, only NYVAC-gpn (ΔFS, Myr-) and NYVAC-C 
coding for GPN were able to induce cross presentation. For both vaccine candidates, CTL 
restimulation was mainly driven by the uptake of infected cells and cell debris. Nevertheless, the 
induced peptide presentation is reduced by a factor of 2.5 than compared with GL9 presentation 
induced by the uptake of cells together with the supernatant (see Fig. D.18). The remaining 
vaccine candidates did not restimulate considerable CTL amounts by cross presentation. Neither 
the uptake of infected HeLa cells nor extracellular immunogens induced cross presentation. 
Peptides derived from VLPs were not efficiently presented on mdDCs. 
Since NYVAC was found to replicate in HeLa cells, to avoid direct presentation the cross 
presentation assay was developed not to exceed a duration of 8 h until CTL cocultivation was 
initiated. Thus, the immunogens present in HeLa cells or the supernatant cannot be quantified by 
Western-blot analysis or ELISA. Due to their insensitivity, immunogen expression can be detected 
not until an incubation period of at least 16 h. 
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Fig. D.21 Experimental layout of cross presentation assays applying transfected HeLa cells 
1x104 HeLa cells cells were infected with the vaccine candidates by MOI 5. After removal of extracellular 
viruses by five washing steps 1 hpi cells were incubated for 3 h. After incubation, the HeLa cells and 
supernatants were separated and cocultivated with mdDC derived from a HLA-B*07+ donor. After incubation 
for 4 h, the mdDC were cocultivated with an equal amount of a GL9-specific T cell clone. After an incubation 
period of 12 h, the T cells were evaluated to express IFN-γ by FACS analysis.  
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Fig. D.22 Cross presentation is mainly driven by the uptake of cell-associated immunogens by 
mdDCs 
5x104 HeLa cells were infected with the indicated vaccine candidates at MOI 5 and incubated for 4 h. Cells 
and supernatant were divided and cocultivated with mdDC for 4 h, followed by GL9 CTL cocultivation. The 
cells were incubated for 10 h, CD8+ CTL were analyzed for IFN-γ expression by FACS analysis.  
 
 
D.7 Different peptides derived from the same HIV-1 antigen 
vary in their direct and cross presentation capacities 
Antigen uptake, processing and presentation on professional APC are strongly dependent on the 
antigen composition (see B.2.2.2 and B.2.2.3). Since surrounding sequences and the peptide 
itself influence proteasomal digestion by positioning the proteasome’s active site to distinct 
regions 151,154,155,260 not every possible peptide present in the antigen is generated by the 
processing machinery. Thus, it is likely that not every single peptide present in an immunogen is 
generated. Due to escape mutations, generation and presentation of several peptide could be 
inhibited. Therefore, direct and cross presentation of a second Gag-derived peptide was 
investigated. For characterization, presentation of a derivative of the best defined and examined 
HIV-1 epitope SLYNTVATL (SL9) was analyzed 228,229. SL9 is an immunodominant HLA-A*2 
restricted help-independent epitope derived from Gag-p17 (residues 77-85). SL9 is found in 
approximately 70% of all HLA-A*2 patients in acute HIV infection whereas in chronic infection only 
a small fraction of patients presented this epitope 230. Due to variations in the amino acid 
sequences in the 97CN54 and 97CN001 isolates, a T cell clone recognizing the HLA-A*2 
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restricted peptide SLFNTVATP was utilized. The direct and cross presentation assay was 
performed as described previously (see Fig. D.14 and D.19). 
Surprisingly, neither direct nor cross presentation of the SP9 peptide could be induced by the 
different immunogens (see Fig. D.23). Although stimulation with the corresponding peptide 
induced restimulation of the SP9 CTLs, no specific immunogen-driven restimulation was 
observed. Since none of the vaccine candidates induced peptide presentation, it is likely that 
peptide generation or presentation is suppressed due to immune escape mutations. Certainly, 
compared to the GL9 CTLs, unspecific SP9 CTL restimulation was determined to be quite 
pronounced. For discussion, see E.3.4. 
 
A 
 
B 
 
Fig. D.23 The HIV-1 p17 peptide SP9 is not presented on mdDCs by direct and cross presentation 
A, SP9 direct presentation: 5x104 mdDCs were infected with the indicated vaccine candidates at MOI 5, 
incubated for 6 h and cocultivated with an equal number of SP9 / GL9 specific CTL for 10 h. CD8+ CTLs 
were analyzed for IFN-γ expression by FACS analysis. 
B, SP9 cross presentation: 5x104 HeLa cells were infected with the indicated vaccine candidates at MOI 5 
and incubated for 4 h.  The HeLa cells were cocultivated for 4 h with 5x104 mdDC followed by cocultivation 
with 5x104  SP9 / GL9 CTL. The cells were incubated for 10 h, CD8+ CTLs were analyzed for IFN-γ 
expression by FACS analysis. 
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E Discussion 
E.1 The vaccine candidates allow expression of HIV-1 derived 
immunogens in HeLa cells and human mdDCs 
So far, no effective HIV-1 vaccine based on the generation of neutralizing antibodies could be 
developed. Due to its partially protective properties, Gag-specific T cell responses are considered 
to be a promising approach for induction of immunity against an HIV-1 infection (see B.1.3.2. and 
B.2.3.2). The vaccine candidate NYVAC-C was designed as a multiepitopic bivalent vaccine 
consisting of both Gag/Pol/Nef (GPN) and gp120 based on the C-clade 97CN54 provirus isolate 
encoded in a poxviral NYVAC vector 243. When analyzing the immunogenicity of the HIV-1 
antigens GPN and gp120 in the phase-I clinical trials EuroVacc01 and EuroVacc02, the induced 
T cell responses were mainly directed against Env. Gag- and Pol-specific T cells were only 
detected at low levels. Thus, a new generation of immunogens based on 97CN54 GPN and Gag 
was developed that were designed to elicit increased Gag expression and therefore enhanced 
immunity. Using NYVAC-C as a reference construct, several immunogen modifications such as 
(i) size reduction, (ii) modulation of Gag versus GPN ratios and (iii) VLP formation capability were 
introduced. The vaccine candidates were designed to elicit efficient immunogen expression in 
tissue cells and professional APC to induce improved direct and cross presentation. In this thesis 
the influence of the modifications on antigen expression as well as direct and cross presentation 
was analysed and compared to NYVAC-C.  
 
First, due to extensive immunodominance of the envelope protein, gp120 was deleted from the 
vector. As predicted, gp120 elimination resulted in increased amounts of intracellular p24. 
Notably, due to Env driven apoptosis 257 (see Fig. D.6), in NYVAC-C infected mdDCs, Gag 
production was completely abolished 8 hpi. The results indicate that apoptotic cells fully disable 
NYVAC replication. In HeLa cells, deletion of gp120 enhances the GPN expression (see Fig. D.3). 
Nevertheless, by NYVAC-C replication detected in HeLa cells it can be demonstrated that Env 
mediated apoptosis is strongly dependent on the cell type 261.  
For enhanced Gag expression, the naturally occurring -1 ribosomal frame shift was reconstituted 
in the artificial GPN polyprotein. In HeLa cells, insertion of a ribosomal frame shift into GPN 
induced an at least 10-fold increase of intracellular Gag steady-state levels (see Fig. D.3). The 
deletion of PN resulted in reduced antigen size and reconstitution of the natural Gag protein-
shape. The size-reduced immunogens were expressed more extensively.  
Due to its large complexicity and artificial origin, (i) expression, (ii) folding and (iii) proteasomal 
degradation of GPN may be altered compared to Gag. Large proteins are frequently described to 
be demanding in production 262. Additionally, GPN folding might be unfavourable for the 
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immunogen expressing cells. This could lead to rapid protein depletion by proteasomal digestion 
that occurs via the ubiquitination pathway (see B.2.2.3.1). Alterations in protein folding can 
redirect ubiquitination complexes resulting in more rapid cleavage 117,147. Rapid co-translational 
digestion initiated by misfolded proteins reduces the intracellular immunogen amount 263.  
For further size-reduction, vaccine candidates coding for Gag were developed. When analyzing 
antigen expression, the NYVAC-gpn (FS, Myr-) induced translation of Gag and GPN in a 95:5 
ratio was strongly diminished compared to production of Gag (Myr-) in HeLa cells (see Fig. D.3). 
This indicates, that expression of GPN limits overall antigen expression. Based on the observation 
that even small GPN levels induced a potent decline of detectable p24, a cytotoxic effect of GPN 
can be assumed. As described before, due to limited antigen expression in NYVAC infected 
mdDCs, this influence can basically be detected in vaccine treated HeLa cells resulting in an 
almost 20-fold increased intracellular p24 concentration (see Fig. D3 A). 
To facilitate cross priming of antigen-derived peptides, vaccine variants coding for budding 
competent Gag were designed. In cells infected by NYVAC-gpn (FS, Myr+) and 
NYVAC-gag (Myr+), VLP formation significantly diminished the intracellular p24 concentration. 
Subsequently after translation, Gag is transported to the cell membrane mediated by cellular 
ESCRT complexes 264,265. There, the myristoylated proteins are anchored into lipid raft regions in 
the plasma membrane which, together with oligomerization promotes, virus particle assembly 21,22. 
Thus, the 5-fold reduced p24 concentration induced by budding competent antigens can be 
attributed to rapid Gag export (see Fig. D.5). This suggests that antigen cross presentation 
capacity is enhanced on the cost of direct presentation ability (see E.3). 
 
Transgene expression was observed to occur in a short time-frame early after infection in both 
mdDCs and HeLa cells. Despite the early expression, minimal immunogen amounts were 
detected in mdDCs. In NYVAC-infected DCs, protein synthesis of late gene products is 
blocked 79,80,81. Since immunogen expression is controlled by an early/late (E/L) promoter, their 
transcription is aborted when reaching late infection phases resulting in declined production. 
Thus, abortive transcription masks differences in expression driven by the immunogen’s 
characteristics. Low-level protein synthesis and the transcriptional block of late genes do not allow 
extensive expression of immunogens. Therefore, the influence of frame shift insertion in the GPN 
polyprotein could not be observed in NYVAC infected mdDC (see Fig. D.7 A). 
 
Taken together, size-reduced immunogen variants triggered the best antigen expression in APC. 
Thus, most efficient peptide direct presentation can be suggested for these immunogens. Due to 
reduced steady-state levels of intracellular Gag proteins elicited by budding competent antigens, 
VLP formation could result in efficient peptide cross presentation.  
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E.2 NYVAC-induced partial mdDC maturation is transgene 
independent 
The major goal in HIV-1 vaccine research is to develop a vaccine that induces long-lasting 
mucosal and systemic immunity. Since viral proteins are often poorly immunogenic, various 
adjuvants have been developed to efficiently enhance immune responses 266,267. By administration 
of subunit vaccines embedding HIV-derived transgenes in an immunogenic viral vector backbone 
efficient immune responses can be generated without applying additional adjuvants 268.   
For efficient T cell activation, upregulation of peptide presenting MHC molecules as well as 
co-stimulatory molecules such as CD80 and CD86 (see B.2.2.1) is required. Due to the 
expression of viral immune regulators, NYVAC infected mdDCs do not undergo a complete 
maturation process. These regulators mainly target cytokines, chemokines and TLR-signalling 
pathways 84. To analyze whether the immunogenic properties of the new generation antigens 
support NYVAC induced mdDC maturation, upregulation of different maturation markers induced 
by the vaccine candidates was monitored. 
The co-stimulatory molecules CD80 and CD86 (also known as B7-1 and B7-2) were not 
upregulated during the maturation process (see Fig. D.8 A to D). However, upregulation of the 
antigen-presenting molecule HLA-DR was observed 12 - 24 h post NYVAC infection. Since 
NYVAC-induced HLA-DR surface concentration did not differ from that elicited by the strong 
stimulant LPS the activation can be considered not to be increasable anymore. At later stages of 
infection, a decline of surface maturation markers was monitored. Due to the observation that LPS 
stimulated mdDC did not downregulate surface presentation of CD80 / CD86 and HLA-DR, a 
NYVAC driven immune escape mechanism can be concluded. Since efficient T cell priming 
requires extensive DC maturation, the downregulation of CD80 and CD86 48 hpi indicates that 
T cell priming is limited to occur within 24 hpi. 
When examining the vaccine candidates’ influence on mdDC maturation, no significant 
differences between the vaccines were detected 24 h post DC infection (see Fig. D.8). A 
decreased surface presentation of maturation markers 48 hpi was found for all candidate vaccines 
except NYVAC-gpn (ΔFS, Myr-). Nevertheless, these data suggest that the antigen’s influence on 
maturation is negligible. Therefore, different CTL restimulation capacities are not dependent on 
mdDC maturation states induced by the vaccine candidates. 
In summary, NYVAC induced maturation was shown to remain incompletely. Upregulation of the 
co-stimulatory molecules CD80 and CD86 was not observed. Due to immune escape 
mechanisms, surface presentation of maturation markers was strongly reduced 48 hpi. The 
antigen itself did not influence maturation or at least only marginally. Since poxviral vectors were 
used for vaccination efficiently (see B.3), T cell priming is not inhibited by incomplete maturation. 
Thus, the vaccine candidates induced CTL restimulation was analyzed further.  
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Admittedly, immune tolerance against HIV derived antigens induced by immature DCs might elicit 
undesired side effects. As described by Mahnke et al., peptide presentation of immature DCs is 
involved in the maintenance of peripheral tolerance, including the induction of T cells with 
regulatory properties 269. 
 
E.3 GL9 derived from the artificial GPN polyprotein is 
presented most efficiently 
Generation of effective CTL responses, a vaccine has to induce antigens presentation efficiently. 
For direct and cross presentation, immunogens present in the cytoplasm are processed 
proteasomaly into peptides. The peptides are transported into the endoplasmatic reticulum where 
they form pMHC complexes that are presented at the surface of DC. These complexes can 
specifically be recognized by T cell receptors (TCR) of CTLs. pMHC recognition by specific TCR 
induces CTL activation 119,120. Besides control of the cell cycle and metabolic pathways 118, 
proteasomal protein processing in particular plays a role in degrading misfolded, unfolded, 
damaged or mutated proteins 116,117. 
Peptide formation by protein proteolysis is directly influenced by the protein’s (i) amino acid 
sequence and (ii) pro-inflammatory environment. Amino acid variations alter ubiquitination and 
proteasomal digestion patterns 144,145,146. Thus, small differences in immunogen composition can 
result in altered peptide processing and cleavage rates 117. Antigen-induced cytokine expression 
can alter proteasome composition and therefore influence degradation 151,156,270. Notably, 
variations in proteasomal processing can be influenced by peptide flanking regions 154,155. An 
immunogen’s cross presentation capacity is strongly influenced by structure and amino acid 
sequence and length of the peptide’s precursor protein 139,140. 
 
E.3.1  The NYVAC vector induces rapid peptide presentation but causes 
undesired effects when being administered at high 
concentrations 
E.3.1.1 Antigen presentation occurs rapidly and is mediated by incompletely maturated DC 
In both, the direct and cross presentation assay, GL9-specific CTL restimulation was observed. 
Although poxviral vectors were described to mainly stimulate T lymphocytes by cross priming 142, 
direct presentation of the GL9 peptide was shown to occur indeed. With NYVAC-infected mdDC, 
up to 30% of the administered GL9 CTL could be activated. Since CTL stimulation requires a 
minimum of several hundreds of pMHC for activation 271,272, efficient GL9 presentation on the APC 
can be considered. With regard to the large amount of (i) alternative HIV-1, (ii) NYVAC derived 
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peptides, and (iii) self-peptides presented on vaccine candiate infected DC, direct presentation 
can be estimated to occur dominantly.  
Remarkably, presentation of GL9 peptides occurs early after mdDC infection with the vaccine 
candidates or infected HeLa cells. As described 272,273, peptide presentation was observed already 
4 h post infection in low and high MOI infections,. Therefore, since mdDCs are found to maturate 
completely within 24 hpi, CTL stimulation by either immature (iDC) or not completely maturated 
DC can be hypothesized 83. On one hand CTL restimulation by iDC could be a benefit as it allows 
T cell activation induced by low peptide presentation levels. On the other hand, low-level antigen 
presentation by iDC is involved in the generation of immune tolerance. Thus, iDC can induce T 
cells with regulatory properties that are suppressing immune responses and therefore suppress 
protectivity 269.  
Aside from the hypothesis, that iDC induce GL9 CTL restimulation, it can be suggested that the 
co-stimulatory molecules CD80 and CD86 are not required for T cell activation ex vivo. Since 
upregulation of HLA-DR but not CD80 and CD86 was observed, the necessity of the 
co-stimulatory molecules to induce GL9 specific CTL is doubtful. Pardigon et al. observed that 
naive CD8+ T cells are fully activated by pMHC complexes alone, but that co-stimulation lowers 
their activation threshold 274. Referring to these findings, a boosted maturation could induce more 
potent T cell responses.  
 
E.3.1.2 For induction of direct presentation but avoiding apoptosis, a balanced 
administration of NYVAC-based vaccines is required 
For both direct and cross presentation, a strong influence of the NYVAC concentration on 
GL9 CTL restimulation was detected. In direct presentation assays, no decline over time could be 
determined in GL9 presentation when applying low MOI (see Fig. D.11 B and D.13). However, 
when administering high virus multiplicities diminished peptide presentation is detected 8 hpi (see 
Fig. D.10 C and D.13). The decline of GL9 presentation could be attributed to peptide dissociation 
as well as a limited peptide half-life of commonly about 6 h 275,276. Due to apoptosis induced by 
high virus multiplicities, the supply of newly generated peptides is interrupted. Together, modest 
protein half-life and NYVAC cytotoxicty decrease antigen presentation strongly. However, since 
APC migration from tissues to lymph nodes is described to occur within one hour 277, the small 
time span of peptide presentation is most likely sufficient for CTL stimulation.  
Due to the observed cytotoxic effects, enhancing direct presentation by administering high virus 
concentrations appears to be inapplicable. When applying NYVAC in a concentration exceeding 
MOI 5, a strong decrease of antigen presentation was observed (see Fig. D.13). The synchronous 
decline observable for all vaccine candidates indicates that cytotoxicity mediated by the vector 
backbone but not by the antigen triggered apoptosis (see Fig. D13). However, due to extended 
apoptosis rates elicited by high MOI infections, the optimal balance between induction of strong 
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immune responses and avoiding cytotoxic effects has to be found for direct presentation. When 
administering NYVAC-based vaccines by injections, local virus concentrations will likely exceed 
multiplicities found to be toxic in vitro.  
In cross presentation assays, high NYVAC multiplicities do not induce a decline in GL9 
presentation. In fact, higher virus concentrations were shown to increase peptide cross 
presentation strongly. Efficient cross presentation is believed to take place in the lymph nodes 
only 278. Cross presentation of pathogen-derived peptides by cells neighbouring infected cells in 
tissues would expose these cells to CTLs. To prevent uninfected but cross presenting cells in 
tissues from CTL induced apoptosis, tolerance against low-level presentation is strongly required. 
Thus, the observed requirement for high immunogen doses in cross presentation could represent 
a protective mechanism. 
In summary, the virus multiplicity can direct the character of peptide presentation. When 
administering low virus amounts, direct presentation is favoured whereas high virus 
concentrations induce mainly cross presentation. Thus, a two-area peptide presentation model 
can be suggested when applying NYVAC-based vaccines by injection. At the entry sites, due to 
high virus amounts mainly cross presentation might be favoured while at distant regions, mostly 
direct presentation occurs. 
 
E.3.2 The new generation antigens do not exhibit enhanced 
immunogenic properties 
E.3.2.1 Enhanced proteolysis induced by non-physiological folding results in enhanced 
GPN immunogenicity  
When comparing the vaccine candidates concerning their ability to induce antigen presentation, 
NYVAC-gpn (ΔFS, Myr-) and NYVAC-C coding for GPN together with gp120 are found to induce 
the most potent direct and cross presentation. Although both variants were shown to elicit only 
modest antigen expression in mdDC as well as HeLa cells, they were able to activate GL9 
specific CTLs extensively. Since mainly the weakly expressed artificial GPN polyprotein gave rise 
to GL9 presentation, efficient antigen presentation did not depend on antigen expression. Rather 
than the amplitude of antigen expression, antigen stability was described to be determining 
efficient peptide presentation 279,280. Protein degradation is believed to be the rate-limiting step for 
adequate antigen presentation by MHC class-I molecules 281,282. For instance, a metabolically 
unstable HIV-1 Nef protein was shown to induce enhanced CTL stimulation accompanied by 
efficient antigen presentation 283. 
Since GPN is simply designed as a large polyprotein neglecting proper folding of the 
corresponding subunits, translation is likely to result in a protein with non-physiological shape. 
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(i) Protein fusions without employing spacer peptides, (ii) scrambling of Nef C- and N-termini, (iii) 
interruption of the RT reading frame, and (iv) insertion of amino acid substitutions probably lead to 
severe protein misfolding. Because of exposure of hydrophobic amino acid residues usually 
embedded in inner regions, misfolded proteins are often insoluble and therefore aggregate in the 
cytoplasm. In vivo, these protein accumulations can result in diseases that range from cancer and 
diabetes to neurodegeneration 284,285. Thus, protein quality control functions to ensure that 
damaged and misfolded proteins are maintained at low amounts to limit their cytotoxic effect 286. 
These defective ribosomal products (DRiPs) represent a large fraction of newly synthesized 
peptides 287. Hence, efficient protein monitoring that comprises refolding by chaperones and 
proteasomal degradation is required to sustain normal cell functions 288.  
Due to its extensive intramolecular modifications, chaperone-mediated protein quality control can 
presumably not reconstitute a native protein shape of the GPN polyprotein. Therefore, other than 
the notably stable Gag protein that displays a metabolic half-life of approximately 6 h 289, GPN is 
likely to be digested rapidly. As described, proteolytic antigen processing is often performed co-
translationally or subsequently after translation 263,290. Proteostasis of misfolded proteins is 
selectively driven by ubiquitination which guides proteins to cytosolic 28S proteasomes for 
degradation 291,292. Thus, rapid proteasomal digestion and not poor expression levels could evoke 
the low GPN amounts detected in Western blot and FACS analysis (see Fig. D.1 and Fig. D.3). 
Next to non-physiological GPN shape, the target protein’s amino acid sequence (e.g. degron 
signals) strongly influences the modification process 144,145,146 resulting in increased proteasomeal 
digestion rates. Hence, enhanced accessibility of immunogen derived peptides and therefore 
broad antigen presentation is elicited 117. Thus, by modified amino acid sequences, GPN could be 
ubquitinated, processed and therefore presented more efficiently than the correctly folded Gag.  
Besides altered proteasomal cleavage rates, variations in the amino acid sequence of Gag and 
GPN could induce differential proteasomal cleavage patterns. When entering the proteasome, the 
internal residues P1, P4 and P5 adjust the peptide in the active site of the proteasome which 
determines processing 151. Since the proteasome is described to be a “multicatalytic 
protease” 148,149 ,150, variations in complex positioning on the target elicit different protein digestion 
results. Additionally, degron- or PEST-sequences inserted in the GPN polyprotein by chance 
could enhance degradation 153. Based on cleavage variations evoked by the amino acid 
sequence, peptide formation is likely to be altered. Alternative peptide composition can affect 
downstream mechanisms involved in peptide presentation. Tap-mediated peptide translocation 
from the cytoplasm to the ER 160 as well as formation of pMHC complexes are strongly influenced 
by the transgene itself 165,166,170 (see B.2.1.3.). 
Taken together, overall folding variations between Gag present in its native conformation and 
GPN captured in a non-physiological protein shape can be considered to be accountable for 
extensive differences in direct presentation. It is likely that protein-folding differences induce 
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variations in (i) patterns and rates of proteasomal digestion, (ii) TAP transport, and (iii) pMHC 
complex formation resulting in different or reduced peptide presentation. Thus, as described by 
Wong et al., the poor immunogenicity of wildtype Gag can be circumvented by targeting defective 
or unstable Gag variants to the proteasomal pathway for rapid degradation 293. It has already 
been shown, that Gag variants enriched for degron signals induced an enhanced T cell 
stimulation 289 
 
E.3.2.2 Low GPN expression induced by insertion of a ribosomal frame shift strongly 
reduces its immunogenicity 
For MHC class-I presentation, protein degradation is described to be the rate-limiting step for 
efficient antigen presentation 281,282 whereas the amount of antigen expression is reported to have 
minor influences 279,280. However, when comparing NYVAC-gpn (ΔFS, Myr-) and NYVAC-gpn (FS, 
Myr-) a strong decrease in direct and cross presentation was observed for GPN (FS, Myr-). Since 
reconstitution of the ribosomal frame shift strongly diminishes GPN expression 250, a correlation 
between antigen expression and peptide presentation is likely. Thus, to enhance an antigen’s 
immunogenicity it has to be optimized for both expression and proteolysis. However, due to its 
size of 160 kDa and extended non-physiological structure, cytopathic effects induced by GPN 
might appear when present at too high concentrations.  
 
E.3.2.3 Gp120 elicits immune stimulation in mdDC resulting in enhanced antigen cross 
presentation  
It has been controversial whether the application of gp120 in a vaccine designed to elicit CTL 
responses is reasonable. Due to enlarged number of possible CTL epitopes, broader immune 
responses could be induced. Certainly, co-administration of HIV-1 gp120 was found to strongly 
diminish antigen expression in APC (see D.3.1 and D.3.2) as well as Gag CTL responses in both 
humans and mice 85,294. Therefore, gp120 is believed to suppress efficient generation of CTL 
responses directed against HIV-1 Gag. 
Surprisingly, despite abortive antigen expression NYVAC-C infected mdDCs are able to stimulate 
CTLs extensively by direct presentation (see Fig. D.11 and Fig. D.13). Thus, cytotoxic properties 
of gp120 observed in NYVAC-C infected mdDC (see E.1 and Fig. D.6) do not inhibit direct 
presentation. As described, the amplitude of antigen expression is shown once more not to be the 
major rate-limiting step for efficient antigen presentation by MHC class-I molecules. However, 
when comparing NYVAC-C and NYVAC-gpn (ΔFS, Myr-) no gp120-mediated benefit on direct 
presentation can be detected (see D.11 A and B). Similarly, gp120 does not influence cross 
presentation in early stages (up to 4 h) of infection (see D.16 B). NYVAC-C only induced 
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enhanced cross presentation observed for extended HeLa-mdDC cocultivation periods. In fact, a 
prolonged Env incubation time on mdDC seems to increase vaccine immunogenicity.  
HIV-1 Env was described to interact with pDCs and mdDCs via the surface receptor DC-SIGN. 
Once taken up, gp120 can influence immune stimulatory signalling cascades by interaction with 
various Toll-like-Receptors (TLR) 295. Furthermore, gp120 was shown to affect mdDC maturation 
and cytokine expression 296,297. Cytokines have immune-stimulatory properties and can assist in 
T cell stimulation. An altered cytokine environment can enhance the vaccine’s immunogenicity. 
Additionally, gp120 was described to induce IFN-γ expression in human PBMC 296. IFN-γ 
influences the proteasome composition resulting in changed catalytic properties 157. These 
immunoproteasomes possess altered substrate properties as well as an enhanced cleavage 
rate 156. Hence, Env driven IFN-γ expression could result in enhanced or altered peptide 
presentation and therefore CTL restimulation. Notably, gp120 induced alterations in TLR 
signalling were observed to mainly influence cross presentation 298,299 whereas induction of 
immunoproteasomes is not exclusive for cross presentation. Thus, the observed gp120 benefit on 
cross presentation is likely not driven by IFN-γ induced immunoproteasomes.  
Taken together, HIV-1 Env influences a vaccine’s immunogenicity. As shown, peptide 
presentation can be modulated by gp120 application. Thus, application of gp120 as an 
immunogen has to be adapted to the applied vector system. When using vectors that induce 
immuno-responses by cross presentation, the co-application of gp120 could boost CTL 
stimulation. 
 
E.3.2.4 VLP formation does not benefit cross presentation  
VLPs represent a form of subunit vaccines that are able to self assemble into an organized 
particle structure 232,233. Since they can efficiently induce cross presentation of HI-viral 
antigens 234,235 several new generation antigens were designed to induce VLP formation. 
Compared to budding incompetent antigens, reduced peptide presentation was observed for 
immuogens that allow VLP formation. Since the p24 steady-state level in mdDC was shown to be 
diminished by VLP budding (see Fig. D.7), it can be concluded that the Gag budding process 
influences direct presentation. Since the physiological shape of Gag was conserved when the 
vaccine candidate’s antigens were designed (see Tab. D.1), co-translational proteolysis can be 
considered to occur rarely. When comparing the protein’s metabolic half-life of 6 h 289 with the 
short time span of 5-10 min required for Gag budding 300, it can be concluded that VLP formation 
takes place before protein degradation occurs. Thus, assembly of Gag particles in the cytoplasm 
as reported for non-myristoylated G2A variants 301 enhances accessibility for proteasomal 
degradation and therefore direct presentation.  
The reduction in direct antigen presentation upon VLP formation was taken due to enhanced 
cross presentation. Certainly, VLPs derived from NYVAC infected HeLa cells were shown not to 
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infect mdDC efficiently. As described, cross presentation is mainly driven by the uptake of 
apoptotic bodies or infected cells 104,138. Antigen presentation induced by HIV-1 Gag derived VLP 
was rarely described to stimulate CTLs 302. In fact, VLPs were observed to elicit mainly CD4+ 
T helper cell and antibody responses, sometimes misleadingly entitled as cross presentation 303. 
Admittedly, induction of VLP-driven immune responses usually requires additional adjuvants 304. 
Since VLPs are often obtained from baculoviral expression systems, immune stimulation 
observed in mice might be induced by non-autologous proteins 305. Thus, co-administration of 
adjuvants could induce cross presentation elicited from VLP produced by autologous cells. 
Nevertheless, the poor immunogenicity of Gag (see E.3.1.3) can not be circumvented by this. 
Rapid, cotranslational proteolysis, required for optimal antigen presentation (see E.3.1.3), is likely 
to inhibit VLP formation. 
 
Taken together, GL9 derived from the artificial polyprotein GPN was observed to be presented 
most efficiently on APC by direct and cross presentation. It can be supposed, that due to 
misfolding GPN is processed more efficiently than the correctly folded new generation 
immunogens.  
 
E.3.3 Antigen immunogenicity is not vector dependent 
The new generation vaccines were designed to elicit higher Gag expression since it was 
estimated that higher Gag amounts would allow for elevated direct and cross presentation. 
Surprisingly, the new generation immunogens did not induce efficient antigen presentation on 
mdDC. Because NYVAC is described to possess multiple immune-escape mechanisms 79,83, its 
influence on antigen presentation was analyzed. Moreover, for the NYVAC related poxviral MVA 
vector, immunodominant vaccinia-specific CTL responses were shown to limit the effectiveness of 
poxviruses in recombinant vaccination strategies 306. Due to immune-escape mechanisms, even 
dominant peptides are frequently not capable of mediating protection against infections. 
Furthermore, the presentation of these unprotective immunodominant peptides can inhibit the 
presentation of protective subdominant epitopes 222.  
To determine whether NYVAC influences or varies cross presentation, an alternative vector 
system was analyzed. To limit immune-escape and application of non-HIV-1 derived antigens, 
plasmid DNA was chosen as a delivery system for the newly designed immunogens. Since 
transfection of mdDC is ineffective and might influence maturation, GL9-presentation was only 
observed in cross presentation assays. Again, only the artificial polyprotein GPN induced efficient 
cross presentation (see Fig. D.20). However, pcDNA3.1-gpn (FS, Myr-) transfected HeLa cells 
were able to modestly induce GL9 cross presentation. Thus, no extensive variations in cross 
presentation induced by NYVAC infected or plasmid DNA infected HeLa cells were detected. 
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Therefore, it can be concluded that NYVAC driven immune-escape does not affect antigen 
presentation. Secondary, since immunogen application by plasmids does not enhance antigen 
presentation a replacement of the GL9 peptide by NYVAC derived epitopes can be excluded.  
In summary, the data indicate that NYVAC does not influence an antigen’s direct and cross 
presentation capacity, although NYVAC possesses broad immunogenic potential and strongly 
influences mdDC maturation.  
 
E.4 Not every single peptide theoretically covered in an 
immunogen is efficiently presented on APC 
For induction of broad immune responses and circumvention of escape mutations, epitope 
enrichment within a single immunogen is discussed to be favourable. So-called mosaic antigens 
are designed to optimize cellular immunologic coverage of global HIV-1 sequence diversity 220. 
These immunogens are assembled from fragments of natural sequences derived from viruses of 
different clades 220. For the development of an all-purpose vaccine, next to enhancing the maximal 
epitope number, MHC-restriction of the encoded peptides has to be considered. All-in-one 
vaccines could be applied globally without being restricted by the vaccinees MHC-environment. 
Nevertheless, it remains unclear whether peptide enrichment is sufficient for the expansion of 
breadth and depth of the immune responses. Since protein structure and amino acid sequence 
strongly influence proteolysis as well as peptide translocation and presentation (see E.3.1.3,) not 
every single peptide theoretically present in an antigen is efficiently generated by the processing 
machinery for presentation on APC.  
To analyze the breadth of antigen presentation on mdDC induced by the newly designed 
candidate vaccines, presentation of the HLA-A*02 restricted p17 SP9 (SLFNTVATP) peptide was 
analyzed. The SP9 peptide encoded in the 97CN54/001 isolate represents a variant of the 
well-known SL9 peptide (SLYNTVATL) 228,229 originated by immune escape mutations. Although 
SL9 was described to be immunodominant, SP9 presentation could not be detected. The absence 
of SP9 presentation could be attributed to (i) altered proteolysis of 97CN54/001 derived antigens 
triggered by escape mutations in the peptide itself or flanking regions, (ii) reduced SP9 
translocation into the ER by the TAP-complex and (iii) a decrease in MHC binding affinities 
compared to SL9. Since SP9 specific CTL can be detected and isolated from HIV-1 positive 
donors with an HLA-A*02 environment, proteolysis and peptide presentation are not inhibited by 
the peptide itself. Certainly, protein folding or peptide flanking regions in the CN54 Gag might 
inhibit SP9 presentation efficiently. Because existence of SP9 specific CTL in the 97CN54 donor 
was not explored, there is no evidence of SP9 presentation elicited by this Gag variant. 
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In summary, it can be stated that epitope maximization does not necessarily result in an 
enhanced number of presented peptides. Since epitopes are found to cluster at distinct regions, 
efficient processing of one peptide might exclude formation of a partially overlapping epitope.  
 
E.5 The artificial polyprotein GPN elicits only weak Gag-
directed CTL responses in Balb/C mice 
For analysis of immunogenicity, safety issues and optimal application routes, Balb/C mice were 
immunized with the NYVAC-based vaccine candidates. The illustrated data (see Fig. E.1) were 
kindly provided by Katharina Böckl (Molecular Microbiology and Gene Therapy Unit, Institute of 
Medical Microbiology and Hygiene, University of Regensburg, Head of Department Prof. Dr. Ralf 
Wagner) 
Briefly, in Balb/c mice, deletion of gp120 did not result in enhanced Gag-specific T cell responses. 
However, enhanced Gag-expression elicited by reconstitution of the natural occurring frame shift 
induces enhanced CD8+ T cell responses. Thus, in the BALB/c mice the immunogenicity of an 
antigen was strongly enhanced by increased Gag steady-state levels. Additional modifications 
such as size-reduction by PN-2deletion or VLP-formation did not further enhance the Gag-specific 
T Cell responses. Hence, in murine in vivo priming assays, immunogen steady-state levels mainly 
influence CTL restimulation. Assuming that the immunogens have similar CTL priming 
characteristics in mice and humans, the poor induction of Gag-specific CTL responses of NYVAC-
C recorded in the EuroVacc studies is most likely not caused by expression of gp120. The low 
immunogenicity is rather due to the weak expression of the artificial GPN polyprotein.  
The influence of direct and cross priming on generating CTL responses can not be evaluated in 
the murine in vivo priming assays. Since budding competence does not increase the Gag-specific 
CD8+ T cell response, it can be concluded that cross presentation elicited by VLPs does not 
account for generating efficient immune responses. 
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Fig. E.1 Illustration of the vaccine candidates’ immunogenicity in in vivo mouse studies as well as 
in vitro antigen presentation assays utilizing human mdDC and GL9 CTL. 
A, Six BALB/c mice (6 weeks old, Janvier) per group were immunized with 1x107 NYVAC viruses. The 
vaccines were applied intramuscularly by injection into the Tibialis anterior. 14 days after immunization, 
splenocytes were isolated and restimulated by the H2d restricted A9I (AMQILKDTI) peptide. In an ICS, CD8+ 
gated cells were analyzed for stimulation by detection of IFN-γ expression.  
B, Human mdDC were infected with different transgenic NYVAC at MOI 5, incubated for 6 h and 
cocultivated with GL9 CTL. The cells were incubated for 10 h, CTL were analyzed for IFN-γ expression by 
ICS.  
C, HeLa cells were infected with different transgenic NYVAC at MOI 5, incubated for 4 h, cocultivated with 
mdDC for 4 h, subsequently followed by GL9 CTL coculturing. The culture was maintained for 10 h. After 
incubation, CD8+ CTL were analyzed for IFN-γ expression by ICS.  
 
Importantly, the conclusions drawn from the mouse model are not in agreement with predictions 
made on the basis of human in vitro direct and cross presentation assays. In these assays, the 
GPN polyprotein induces best antigen presentation whereas antigen expression levels and VLP 
budding were shown to influence antigen presentation only slightly. The variations observed for 
both models could be attributed to (i) MHC type-dependent peptide presentation, (ii) variations in 
peptide presentation in murine and human APC, (iii) differences in TCR repertoires and thymic 
selection and (iv) discrepancies between T cell stimulation in vivo and restimulation in vitro. 
 
As shown by the differences observed for antigen presentation of the HLA-B*07 restricted GL9 
and HLA-A*02 SP9 peptides, the peptide component of the pMHC complex has a strong influence 
on CTL restimulation. Peptide presentation by certain MHC complexes was shown to induce 
protective CTL responses whereas other HLA-types failed to mediate protection (see B.2.2.2). 
Thus, the ex vivo stimulation assays of human CTL and murine the in vivo responses in the 
murine model are of limited comparability, because the HLA systems of both organisms show 
broad variations. Since the major part of the T cell receptors bind to HLA-subunits of the pMHC 
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complex, variations in the MHC environment and thymic selection between both species could 
induce differences in the T cell receptor repertoire. Thus, peptide presentation in mice and 
humans can differ among each other. The observed immune responses might be exclusive for 
Balb/C mice. 
 
Due to differences in protein degradation depending on the proteasome composition, variations in 
peptide processing might be elicited by different proteolysis patterns of human und murine 
proteasomes 156,307. Additionally, the TAP-dependent peptide translocation from the cytosol to the 
ER was shown to be peptide-specific and could vary between both species (see B.2.1.3.2).  
 
Although differences in proteolysis, peptide translocation and presentation among mice and 
humans could alter an antigen’s immunogenicity, variations are most likely elicited by differences 
between T cell stimulation in vivo and restimulation of CTL clones in vitro. In vitro priming of naïve 
CD8+ T cells was described to be ineffective and requires artificial cell settings that do not 
correspond to the physiological priming in the lymph node 308,309. Therefore, an in vitro assay 
utilizing already primed HIV-Gag specific T cell clones was applied. In contrast to CTL stimulation 
in in vivo assays, CD4+ T helper cells are dispensable for ex vivo CD8+ restimulation 310. Hence, 
restimulation of specific CTL is not as restricted as activation of naive CD8+ cells. Furthermore, 
CTL restimulation already occurs with lower numbers of pMHC complexes compared to 
stimulation. Thus, restimulation of CTL clones derived from HIV-1 infected donors can occur 
despite limited peptide presentation.  
Additionally, in an in vivo assay, the viruses are not distributed equally among the cells next to the 
injection site. As shown for ex vivo direct and cross priming assays, the virus concentration 
strongly influences the character of peptide presentation by APC. Thus, differences observed 
between in vivo and ex vivo could be elicited by varying virus amounts. 
 
In summary, extensive variations in the immune system between mice and humans hamper the 
comparability between both species. The human ex vivo assays allow analysis of the antigen’s 
capacity to be presented on APC. Nevertheless, due to the non-physiological conditions, 
demonstrated antigen presentation does not necessarily result in increased immunogenicity.  
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E.6  Outlook 
In direct and cross presentation assays, only low immunogenic capacities of physiologically 
shaped new generation Gag-variants were observed whereas the artificial polyprotein GPN 
induced extensive peptide presentation. In the clinical phase-I trial EuroVacc02, NYVAC-C 
(coding for GPN and gp120) was shown to elicit only weak Gag, Pol and Nef specific 
CTL-responses in humans. As shown, without co-administration of the gp120 protein direct 
presentation was significantly increased. Thus, in vivo application of NYVAC-gpn (ΔFS, Myr-) 
could induce higher Gag, Pol and Nef specific CTL-responses in humans. Additionally, enhanced 
GPN-expression could amplify its immunogenicity in humans. Increased expression can be 
achieved by codon optimization or modifications of regulatory elements such as the insertion of a 
stronger promoter or enhancer elements. Since the expression of late poxviral gene products is 
inhibited in APC, poor expression could be circumvented by immunogen application with another 
vector system. Viral vectors such as Adenoviruses that infect APC could elicit direct presentation 
and therefore induce CTL responses more efficiently. Additionally, immune-escape mechanisms 
characteristic for NYVAC resulting in poor APC maturation could be avoided. More extensive APC 
maturation could result in increased peptide presentation and therefore enhance T cell priming. 
However, when applying alternative vector systems, (i) elicitation or side effects, (ii) pre-existing 
immune responses and (iii) immunodominance of vector-own antigens have to be excluded. 
To enhance immunogenicity of HIV-1 Gag, variants with non-physiological protein shape leading 
to rapid degradation could be developed. By interrupting the native Gag-folding e.g. by scrambling 
particular subunits, proteasomal digestion might be enhanced. To detect Gag variants with 
optimal immunogenicity, a library of scrambled Gag-variants could be generated and screened in 
CTL-restimulation assays.  
An alternative and promising approach to generate immunogens that induce broadly protective 
CTL is the development of so-called mosaic-antigens. Gag-based mosaic antigens are designed 
to contain a maximized number of epitopes that cover the HIV-1 sequence diversity 220. At the 
Molecular Microbiology and Gene Therapy Unit of the University of Regensburg, a new 
bioinformatic algorithm for the design of epitope-enriched mosaic-antigens has been developed. 
By this algorithm, an array of Gag-based immunogens with user-defined characteristics can be 
designed. To determine antigen presentation capacity of such newly developed mosaic-antigens, 
they have to be screened for direct and cross presentation in a CTL-restimulation assay. 
 
In a murine in vivo assay, enhanced Gag steady-state levels induced increased Gag-specific CTL 
responses whereas in an human ex vivo system antigen presentation could not be increased by 
an enhanced Gag expression-rate. Thus, to determine the validity of the results obtained with 
these assays, further studies that explain the discrepancies between both assays are required. 
Therefore, analysis of the new generation vaccine candidates in outbred mice with enhanced 
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genetic diversity together with a non-human primate study could demonstrate the relevance of the 
results obtained in this work. Detection of antigen presentation by restimulation of various CTL 
clones in a more extensive ex vivo assay could support the results obtained from in vivo studies. 
A reliable method that simulates CTL activation in humans accurately could help to design 
immunogens more efficiently. 
 
 
Although the newly designed immunogens analyzed in this study did not exhibit antigen 
presentation capacity to the desired degree, the results are likely to guide the rational design of 
Gag-based CTL vaccines. The consideration that a non-physiological shape of a protein strongly 
enhances its antigen presentation-rate should be the starting point for a next generation of 
antigens with increased immunogenic features.  
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F  Appendix 
F.1 Abbreviations 
If not stated otherwise, abbreviations follow the recommendations from the Chicago Manual of 
Style 311, and biochemical abbreviations follow the Gold Book of IUPAC 312 and the list of common 
abbreviations by the Journal of Biological Chemistry 313. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IN HIV-1 integrase 
IL interleukin, subgroup of cytokines 
ESCRT endosomal sorting complex required 
for transport 
EV extracellular virions 
EV01 EuroVacc01, HIV vaccine phase-I 
clinical trial  
EV02 EuroVacc02, HIV vaccine phase-I 
clinical trial  
FACS fluorescence activated cell sorting 
FasL Fas ligand, type-II transmembrane 
protein that induces apoptosis 
FCS fetal calf serum 
Fig figure 
FITC Fluorescein isothiocyanate 
FSC forward scatter 
Gag group-specific antigen 
GL9 HIV-1 Gag p24 derived peptide, 
GPGHKARVL 
GM-CSF granulocyte macrophage colony-
stimulating factor 
GNE8 GNE8 rgp120 C-Clade HIV-1 strain 
gp glycoprotein 
GPN artificial Gag-Pol-Nef polyprotein 
HAART highly active anti-retroviral therapy 
HeLa Henrietta Lacks, cervix carcinoma 
derived cell line 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HLA-DR MHC class II cell surface receptor 
allele 
HRP horseradish peroxidase 
hpi Hours post infection 
ICS intracellular cytokine staining 
IFN interferon 
Ig immunoglobulin 
97CN001 HIV-1 C-Clade provirus isolate 
97CN54 HIV-1 C-Clade provirus isolate 
A224 HIV-1 C-Clade gp120 isolate 
Ad5 Adeno serotype 5 
AI9  
AIDS aquired immunodeficiency syndrome 
AIDSVAX B/B HIV-1 vaccine consisting of 
recombinant B- and C-Clade gp120 
ALVAC canarypox virus 
APC antigen presenting cell 
APC-Cy7 allophycocyanin-cyanine7 dye 
Balb/C albino, laboratory-bred mouse strain 
BFA brefeldin A 
BHK-21 baby hamster kidney cells 
bp base pairs 
C57BL/6 inbred strain of laboratory mice 
CCR chemokine (C-C motif) receptor 
IL interleukine 
CD cluster of differentiation 
CEV cell-associated enveloped virions  
CTL cytotoxic T lymphocyte 
CTLA cytotoxic T-lymphocyte antigen  
CXCR C-X-C chemokine receptor 
DC dendritic cell 
DF-1 chicken embryo fibroblast cell line 
DMEM Dulbecco's modified Eagle  
medium 
DNA  deoxyribonucleic acid  
dsRNA double-stranded RNA 
E/L early/late 
EBV Epstein-Barr-Virus 
EDTA ethylenediaminetetraacetic acid 
eIF-2a eukaryotic translation initiation factor 
2A 
Env HIV-1 envelope protein 
ER endoplasmic reticulum 
Contents  91
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV immature viral 
LAI B-Clade HIV-1 strain 
LB lysogeny broth 
LCL human B lymphoblastoid cell lines 
LDC Langerhans cell, mDC subpopulation 
LCMV Lymphocytic Choriomeningitis virus 
LPS lipopolysaccharides 
LTR long terminal repeat 
Ma HIV-1 matrix protein 
MACS magnetic-activated cell sorting 
mDC myeloid dendritic cell 
mdDC monocyte derived dendritic cell 
MHC major histocompatibility complex 
MIP macrophage inflammatory protein 
MOI multiplicity of infection 
MRK-Ad5 AIDS vaccine candidate based on 
Ad5, developed by Merck KGaA 
mRNA messenger RNA 
MTBS TBS buffer compounded with 5% skim 
milk powder   
MV mature virion 
MVA modified vaccinia ankara 
Myr myristoylation 
NC nucleocapsid 
Nef negative regulatory factor 
NFkB nuclear factor 'kappa-light-chain-
enhancer' of activated B-cells, 
transcription factor 
NYVAC New York Vaccinia, vP866 
OD optical density 
ORF open reading frame 
PBS phosphat buffered saline 
pDC plasmacytoid dendritic cell 
PEST proline, glutamic acid, serine, and 
threonine rich sequences 
PHA-L Phytohaemagglutinin agglutinating 
leukocytes 
PIC pre-initiation complex 
pMHC peptide-MHC complex  
pMHC:TCR peptide-MHC-TCR complex  
Pol HIV-1 polyprotein 
PR HIV-1 protease 
Rev HIV-1 regulator of virion 
RIPA radioimmunoprecipitation assay buffer 
RNA ribonucleic acid 
RPMI Roswell Park Memorial Institute 
medium 
RRE Rev-responsive element 
RT HIV-1 reverse transcriptase 
RTC reverse transcription complex  
RV144 HIV vaccine phase-III clinical trial  
SDS-PAGE sodium dodecyl sulfate polyacrylamide 
gel electrophoresis 
SL9 HIV-1 Gag p17 derived peptide, 
SLYNTVATL 
snp single nucleotide polymorphism 
SOB super optimal broth 
SOC SOB containing glucose 
SP9 HIV-1 Gag p17 derived peptide, 
SLFNTVATP 
SSC side scatter 
STI structured treatment interruptions 
Tab table  
TAP Transporter associated with antigen 
processing 
Tat transactivator of transcription 
TB Transfomation buffer 
TCA trichloroacetic acid 
TCGF T cell growth factor 
TCR T cell receptor 
TE Tris-EDTA buffer 
TLR Toll-like receptor 
wt wild type 
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F.2 Characteristics and functions of surface molecules, 
chemokines and cytokines 
Surface molecules and receptors 
CCR5 chemokine (C-C motif) receptor, mediating inflammatory responses, expressed on T cells, DC and 
macrophages 
CD4 coreceptor for T cell activation by TCRs, expressed on T cells 
CD8 coreceptor for T cell activation by TCRs, expressed on T cells 
CD14 monocyte surface marker, co-receptor for LPS detection 
CD28 co-stimulatory molecule necessary for T cell activation, expressed on T cells 
CD40 co-stimulatory molecule, expressed on APC 
CD40L CD40 ligand, expressed on T cells 
CD80 also B7-1, co-stimulatory molecule necessary for T cell activation, expressed on monocytes 
CD86 also B7-2, co-stimulatory molecule necessary for T cell activation, expressed on APC 
CTLA4 cytotoxic T-lymphocyte antigen 4, transmits an inhibitory signal to T cells, expressed on T cells 
CXCR4 C-X-C chemokine receptor type 4, chemotactic agent, expressed on T cells 
DC- 
SIGN 
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin, C-type lectin 
receptor, expressed on DC 
DC- 
LAMP dendritic cell lysosome-associated membrane glycoprotein, expressed on DC 
  
Chemokines and cytokines 
IFN-a type I class interferon, innate immune response modulator, expressed by leukocytes 
IFN-g 
type II class of interferon, innate and adaptive immune response regulator, expressed by 
lymphocytes and NK cells 
IL-1 regulator of immune responses, inflammatory reactions 
IL-15 stimulation and maintenance of cellular immune responses 
IL-4 stimulation of activated B-cell and T-cell proliferation 
MIP-1a 
Chemokine (C-C motif) ligand 3, proinflammatory activities such as leukocyte chemotaxis, 
expressed by macrophages 
MIP-1b 
Chemokine (C-C motif) ligand 3, proinflammatory activities such as leukocyte chemotaxis, 
expressed by macrophages 
MIP3a 
Chemokine (C-C motif) ligand 20, proinflammatory activities such as lymphocyte chemotaxis, 
expressed by macrophages 
RANTES 
Regulated upon Activation, Normal T-cell Expressed, and Secreted, Chemokine (C-C motif) ligand 
5, proinflammatory activities such as T cell chemotaxis 
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